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Abstract
Learning and memory are complex processes: many signaling pathways must
come together to start the process of long-term potentiation (LTP), an improvement in the
connection between two neurons as a result of a previous signal. LTP involves both the
TrkB and NMDA receptor signaling cascades, and there is evidence to support cross-talk
between TrkB and the NMDA receptor subunit NR2B using adaptor proteins. ShcC is
thought to be involved in learning and memory as ShcC knockout mice have increased
hippocampal LTP and better performance in Spatial Memory tasks (Miyamoto et al.,
2005). Our results indicate that ShcC binds to both Fyn and Src, likely through CH2 and
SH2 domain interactions, and is facilitated by phosphorylation of three tyrosines in the
internal CH1 domain.

Keywords
LTP, TrkB, Neurotrophins, BDNF, ShcC, MAP Kinase, NMDA, Glutamate, Tyrosine
Phosphorylation.
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Chapter 1. Introduction
Human intelligence can be attributed to, at a molecular level, the transmission of
an electrical signal from one neuron to the next; much like the feeling of pain is
transferred along a synapse from its site of origin to the brain. The mammalian brain, in
addition to receiving such electrical signals, is capable of storing and retrieving them as
memories; a phenomenon which is, to date, not well understood. The human brain is
unique in many regards, most notably speech, emotion, and higher learning, but the
underlying mechanisms are remarkably similar to our mammalian counterparts. This
allows researchers to use animal models to study the learning process. With the
technological advancements made in the century, the steps of the learning process are
finally coming to light. Science is coming close to understanding how learning and
memory are achieved at a molecular level and, hopefully, with time, we will understand
the molecular basis of learning disorders and develop new technologies for their
treatment.
1.1

The Phenomenon of Learning and Memory.
Learning and memory arise from synaptic plasticity in the brain - either

strengthened or diminished connection between two neurons. There are two types of
memory: long-term and short-term. The latter arises from changes in protein activity;
while the former is maintained by synthesis of new proteins (Xia et al., 1996). The two
main forms of synaptic plasticity are long-term potentiation and long-term depression.
Long-term potentiation (LTP), i.e. the improved communication between two neurons as
a result of a previous signal, is commonly regarded as the key mechanism behind
learning and memory. Long-term depression (LTD), i.e. a weakened connection between
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two neurons, is also involved in learning and memory, but will not be elaborated further.
Long-term potentiation can be further divided into early, or classical, and long-lasting
LTP (E-LTP and L-LTP, respectively). Classical, or early, LTP proceeds without
synthesis of new proteins, and thus requires only changes in the activity of existing
proteins (short-term), whereas long-lasting LTP, which can continue for days, requires
transcription and synthesis of new proteins (Xia et al., 1996). Long-term memory (LTM)
formation and storage is not as well understood, but is thought to involve persistent
changes in neuronal functionality and repeated activation of signaling pathways over long
periods of time (Eckel-Mahan et al., 2008; Mozzachiodi et al., 2008).
It is commonly known that neurons have two main functional sites: in addition to
the cell body (containing the nucleus), neurons have both dendrites, which serve to
receive signals from other stimuli, such as other neurons; and one central axon, which
serves in turn to transmit signals from one neuron to the next. In a synaptic chain, the
neuron which transmits a signal, from the axon, is termed the pre-synaptic neuron.
Alternatively, the neuron which receives a signal in the dendrites is called the postsynaptic neuron. More specifically, small protrusions on the dendrites, called dendritic
spines, contain all the proteins involved in learning and the induction of LTP, in a small
protein-rich structure called the post-synaptic density (PSD), which will be elaborated
further in section 1.2. In addition, dendritic spines have been shown to expand in size
during the induction of LTP (Lang et al., 2004; Matsuzaki et al., 2004). Moreover, LTP
can also be thought of as having two components, the traditional post-synaptic
component, as well as the slower, pre-synaptic component where there are also
modifications taking place (Bayazitov et al., 2007).
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There are many kinds of synaptic plasticity, but the most commonly studied form
with respect to learning is in response to the neurotransmitter glutamate, termed
glutaminergic signaling. The hippocampus is also the most commonly studied site of
learning (Minichiello et al., 2002). There are many pathways involved in this kind of LTP
which include, but are not limited to the Trk receptor family and downstream signaling,
including the Shc family of adaptor proteins, AMPA and NMDA receptor signaling, and
their subsequent regulation by Fyn (Src family kinases) and Striatal-Enriched Protein
Tyrosine Phosphatase (STEP). The Trk family of receptors facilitate a number of
signaling pathways, which will be discussed in further detail in section 1.3, but the most
important pathway with respect to its role in learning and memory is the phospholipase
Cγ (PLCγ) pathway. It has been shown that point mutations in the TrkB receptor at the
binding site for PLCγ (Tyrosine 816) result in an impairment of hippocampal LTP,
whereas point mutations in the Shc binding site (Tyrosine 515) do not (Minichiello et al.,
2002). It is also known that PLCγ signaling through TrkB activates cyclic-AMP
responsive element-binding protein (CREB), a transcription factor responsible for
induction of many LTP-dependent genes (Minichiello et al., 2002). In addition, CREB
can also be activated, via phosphorylation at Serine 133, in response to Erk/MAPK
signaling and also to glutamate, a key neurotransmitter in synaptic plasticity and learning
(Xia et al, 1996; Eckel-Mahan et al., 2008). Glutamate, when released during synaptic
transmission

activates

two

key

receptors:

α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid (AMPA), and N-methyl-D-aspartate (NMDA), ionotropic
glutamate receptors which generally serve as ion channels to sodium and potassium, and
calcium ions, respectively (Hollmann et al., 1991; Xia et al., 1996). In fact, calcium
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influx via the NMDA receptor is often viewed as a critical step in the induction of LTP
(Xia et al., 1996). AMPA and NMDA receptor functions in LTP will be further described
in section 1.5.
Calcium influx via the NMDA receptor induces a number of cellular changes,
whether direct or indirect, including alterations in tyrosine phosphorylation of proteins
involved in learning, such as Src (Lu et al., 1998). In fact, blockade of Src activity
prevented LTP in rat hippocampal neurons (Lu et al., 1998). NMDA receptors have also
been shown to induce transcription of LTP-dependent genes, namely c-fos, via the
MAPK/Erk signaling pathway (Xia et al., 1996). Lastly, the expansion of dendritic spines
is also shown to be dependent on NMDA receptors (Matsuzaki et al., 2004).
Neurotrophins, namely brain-derived neurotrophic factor (BDNF), have also been shown
to play a role in LTP, through independent pre-synaptic and post-synaptic elements
(Alder et al., 2005). BDNF-induced synaptic plasticity is regulated by cyclic AMP
(cAMP), a messenger required for many functions of BDNF (Ji et al., 2005). In addition,
both pre-synaptic and post-synaptic components of TrkB/BDNF-mediated LTP are
regulated by the PLCγ signaling pathway (Gartner et al., 2006).
In addition to structural and functional remodeling upon LTP induction, synapses
can also be functionally remodeled in a more permanent capacity. Drug abuse can
significantly impair neuronal excitability and consequently impairment in synaptic
plasticity is thought to be the transitioning factor to addiction (Kasanetz et al., 2010).
Alternatively, there is evidence to support that conditioning can positively alter the basal
excitability of a neuron such that memory persists, providing a possible mechanism for
long-term memory storage in Aplysia (Mozzachiodi et al., 2008). Recently, it was also
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discovered that many proteins involved in long-term memory are subject to oscillations
with respect to circadian rhythm. In particular, adenylyl cyclase activity and subsequent
cAMP levels, Erk and MAPK phosphorylation, and CREB Serine 133 phosphorylation
were all significantly higher during the day (Eckel-Mahan et al., 2008). It has also been
shown that circadian rhythm is important in memory persistence, as there was a deficit in
fear memory in mice that were subject to all-dark conditions (Eckel-Mahan et al., 2008).
1.2

The Post-Synaptic Density: A Site for Learning.
Learning and memory processes are initiated at the cell surface; the synapse of

neurons located at dendritic spines receives signals from the pre-synaptic neuron via its
axon, and transmits the signal further down the chain. More specifically, the site of
synaptic transmission is a protein-dense region called the post-synaptic density (PSD),
marked by an enrichment of the scaffolding protein post-synaptic density 95 (PSD-95;
Cho et al., 1992). PSD-95 contains two PDZ domains and an SH3 domain, and the PDZ
domains are known to bind receptors such as the NMDA receptor through its subunit
NR2B and serve to anchor kinases such as Fyn or Src to the PSD, and mediate regulatory
processes such as tyrosine phoshorylation of NR2A and NR2B by Fyn kinase (Tezuka et
al., 1999).
Over the decades, there have been several key articles with regards to isolating the
post-synaptic density by subcellular fractionation and to further characterize its
constituents. First and foremost, it was found that synaptic membranes separate with the
mitochondria upon centrifugation, making the technique a useful tool for isolating
synaptic membranes (De Robertis, 1967). Next, researchers began to optimize conditions
to remove the synaptosomal plasma membrane from mitochondrial contamination,
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including the addition of an osmotic shock, and the removal of alkaline phosphatase via
addition of Triton X-100 (Cotman and Matthews, 1971). It was also concluded that
polypeptides were the major component at this time (Cotman and Taylor, 1972). In fact,
the PSD, which could be isolated from the brain and even from the synaptic membrane,
was set up as a polypeptide matrix potentially formed by a single polypeptide and small
amounts of other proteins of varying sizes (Cotman et al., 1974; Banker et al., 1974).
Afterwards, researchers began to characterize proteins present in the post-synaptic
density by size, and believed that actin and neurofilaments were present, but little to no
tubulin (Cohen et al., 1977; Blomberg et al., 1977). Later, many proteins, some receptors,
were added to the list of proteins in the PSD such as AMPA receptors, Calmodulin,
CaMKII, NMDA receptors, TrkB, and the scaffolding protein PSD-95 (Wu et al., 1996;
Ji et al., 2005; Swulius et al., 2010). The levels of each protein present in the PSD vary at
different developmental stages, with structural data also showing that the PSD changes
drastically throughout development (Swulius et al., 2010). In turn, each protein is
regulated and receptors are turned over in an activity-dependent manner, utilizing the
ubiquitin proteasome system (Ehlers, 2003).
1.3

Trk Receptor Signaling and Neurotrophins.
The Trk family of Receptor Tyrosine Kinases serve a pivotal role in the growth

and survival of terminally differentiated, post-mitotic neurons. There are three Trk family
members: TrkA, B, and C which are expressed in the brain and bind specific
neurotrophins. TrkA binds specifically to NGF, TrkB to BDNF and also to neurotrophin4/5 (NT-4/5), and TrkC to NT-3 (Kaplan et al., 1991; Klein et al., 1993; Lamballe et al.,
1993). TrkB, which is expressed solely in the nervous system, is regarded as the key Trk
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receptor in learning and memory (Klein et al., 1989; Klein et al., 1990) and will be the
subject of further discussion in this section.
Throughout the brain, BDNF and TrkB have been shown to be involved in spatial
memory, associative learning, fear learning, and object recognition memory (Mizuno et
al., 2003; Gruart et al., 2007; Musmeci et al., 2009; Hopkins and Bucci, 2010), and have
involvement in cortical development, neurite outgrowth, dendritic development, dendritic
spine density, and synaptic plasticity (Bartkowska et al., 2007; Meakin et al., 1999;
Alonso et al., 2004; Finsterwald et al., 2010; Crozier et al., 1999; Alder et al., 2005).
Furthermore, BDNF and TrkB have been implicated in both Limbic Epileptogenesis and
Huntington Disease (He et al., 2010; Ginés et al., 2010). The biological significance of
TrkB (and BDNF) was shown when Klein et al (1993) attempted to engineer TrkB
mutant mice, lacking a functional tyrosine kinase domain, which died shortly after birth
due to large nervous system defects and poor motor control and breathing (Klein et al.,
1993). A conditional knock-out of TrkB in the postnatal forebrain produced mice with
impairment in hippocampal LTP and complex learning tasks such as Morris Water Maze,
which tests the hippocampal-dependent spatial learning, while succeeding at less difficult
tasks, such as passive avoidance (Minichiello et al., 1999). This led researchers to believe
the mice had a problem adapting to stress (Minichiello et al., 1999).
As with all receptors, TrkB activates a number of downstream signaling pathways
which lead to many cellular functions such as growth, survival, and gene transcription.
For simplicity, only a set group of proteins that are shown to bind will be discussed. The
TrkB receptor itself is a dimer, with two identical subunits containing both intra- and
extra-cellular regions, as well as a transmembrane region (Klein et al., 1989). The
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intracellular region contains a tyrosine kinase domain which contains two main sites for
downstream signaling cascades: Tyrosine 515 (Y515), for Shc or FRS2 competitively,
and Tyrosine 816, for PLCγ (Klein et al., 1989; Meakin et al., 1999; Minichiello et al.,
2002). In addition, the Plekstrin Homology domain (PH1) of Ras-Guanine releasing
factor 1 (RasGRF1), a nucleotide exchange factor for the small GTPase Ras and Rac, has
been shown to bind to TrkB through its HIKE domain, whereby Trk phosphorylates
RasGRF1 and potentiates neurite outgrowth in response to both NGF (Robinson et al.,
2005) and BDNF (Talebian et al., 2012). The Shc site, at Tyrosine 515, leads to
activation of MAP kinase, while the PLCγ site, at Tyrosine 816, leads to activation of
downstream CREB signaling (Minichiello et al., 2002). TrkB, through interaction with
Shc, can give rise to neuronal growth and survival through either PI3-Kinase or
MAPK/Erk (Atwal et al., 2000). Through PLCγ and related signaling, TrkB can give rise
to LTP (Minichiello et al., 2002). The PLCγ site is also essential for hippocampal LTP:
mice lacking a Tyrosine at residue 816 had a significant reduction in LTP (Minichiello et
al., 2002). In fact, PLCγ signaling supports both pre- and post-synaptic hippocampal LTP
(Gartner et al., 2006). Though not indicated by this experiment, ShcC may also play an
alternative role in LTP and learning. ShcC knockout mice have an enhancement of LTP
in the hippocampus, and better performance in many hippocampal-dependent tasks, such
as Morris Water Maze (Miyamoto et al., 2005).
Upon BDNF binding, active TrkB undergoes tyrosine phosphorylation, leading to
the binding of PLCγ, Shc and/or FRS2 (Klein et al., 1989; Kaplan et al., 1991;
Minichiello et al., 2002; Meakin et al., 1999). The PLCγ signaling cascade leads to
downstream Calcium/Calmodulin kinase activation, CamKII and CaMKIV in particular,
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and CREB activation, leading to gene transcription and synaptic plasticity, namely LTP
(Minichiello et al., 2002).

Upon Shc binding, there is recruitment of Grb2 and

downstream transient activation of the MAP kinase signaling cascade leading to growth
and survival (Rozakis-Adcock et al., 1992; Minichiello et al., 2002). ShcB and C are also
capable of binding to TrkB at this site and eliciting the same response (Liu and Meakin,
2002). Upon FRS2 binding to Tyrosine 515, FRS2 also binds to Grb2, but subsequently
binds to Crk/p38, Sh-PTP-2/Shp2, and Src leading to differentiation, or neurite outgrowth
in vitro, though it may also activate or prolong MAPK signaling (Meakin et al., 1999).
For a schematic representation of TrkB signaling, see Figure 1.
Brain-derived neurotrophic factor also plays a role in modulating synaptic
plasticity in the hippocampus. BDNF administration, opposed to NGF, was shown to
enhance NMDA receptor activity, indicating some specificity among the neurotrophins
(Levine et al., 1998). Similarily BDNF, but not NT-3, was shown to increase the tyrosine
phosphorylation of the NMDA receptor subunits NR1 and NR2B indicating there is some
cross-talk between TrkB receptor signaling and NMDA receptors (Suen et al., 1997;
Levine et al., 1998; Lin et al., 1998). Interestingly, interference of NR2B-containing
NMDA receptors with ifenprodil, an NR2B inhibitor, prevents the effects of BDNF on
synaptic plasticity, providing further evidence for cross-talk between TrkB and NMDA in
LTP (Crozier et al., 1999). BDNF has also been shown to increase the tyrosine
phosphorylation of the AMPA receptor subunit GluR1, though this effect is dependent on
NMDA receptor activity as well (Wu et al., 2004). This effect is not only seen in the
hippocampus; BDNF has also been shown to influence NMDA-mediated LTP in the
spinal cord, where it may contribute to inflammatory pain responses (Kerr et al., 1999).
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Figure 1. Schematic representation of TrkB signalling that leads to differentiation,
neurite outgrowth, LTP, and neuronal survival. Briefly, activation of TrkB by BDNF
leads to phosphorylation of Tyrosines 515 and 816, which serve as recruitment sites for
Shc/FRS2 and PLCγ, respectively (Minichiello et al., 2002). This leads to activation
of many downstream signalling pathways including MAPK/Erk, and CREB (RozakisAdcock et al., 2002, Minichiello et al., 2002). Activation of MAP kinase through Shc
has been shown to mediate neuronal growth and survival (Rozakis-Adcock et al., 1992;
Minichiello et al., 2002); whereas FRS2 binding is thought to lead to neurite ourgrowth
and differentiation, and potentially additional or prolonged MAPK activation (Meakin
et al., 1999). Alternatively, binding of PLCγ to TrkB has been shown to activate
downstream CREB signaling and subsequently lead to LTP (Minichiello et al., 2002).
Image adapted from Minichiello (2009).
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1.4

The Shc Family of Adaptor Proteins.
To date, there are four identified Shc family members: ShcA (abbreviated Shc),

ShcB, ShcC, and recently characterized, ShcD. They are structurally similar but vary in
sequence (Sakai et al., 2000). While ShcA is expressed ubiquitously through the body, its
expression is tightly controlled in the brain during development, and reduced to very low
levels after birth (Conti et al., 1997). ShcB is found to be expressed widely throughout
the developing nervous system, particularly strongly in the dorsal root ganglion and
superior cervical ganglion, involved in sensory and sympathetic systems, respectively
(Sakai et al., 2000). ShcC is expressed only in the nervous system, as shown by mRNA
and protein studies, where protein expression is low during development and rises at birth
(Nakamura et al., 1998; Sakai et al., 2000). There is evidence that ShcB and C govern the
maintenance of different types of neurons, based on their differential expression patterns
across the brain (Ponti et al., 2005). For example, ShcB is greatly enriched in primary
sensory neurons and olfactory nerve fibers, whereas ShcC is enriched in the striatum and
motor fibers (Ponti et al., 2005). In addition, ShcB mRNA is detectable in the adult
peripheral nervous system, where ShcC mRNA is not (Nakamura et al., 1998). ShcD, the
most recently identified Shc family member, is expressed in both the adult brain and
skeletal muscle, in particular at the neuromuscular junction, and has the most similarity to
ShcA (Jones et al., 2007). During development, ShcD is expressed, widely throughout the
body but also in the brain (Hawley et al., 2011).
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Figure 2. Schematic representation of the adaptor protein, ShcC, expressed in the
brain. There are two isoforms, 69 and 55 kDa, differing in the presence of an Nterminal Collagen-Homology 2 (CH2) domain (O’Bryan et al., 1996). Both isoforms of
ShcC contain two phosphotyrosine-binding domains, PTB (N-terminus) and SH2 (Cterminus), with an internal, Collagen Homology 1 (CH1) domain containing three
tyrosines which, when phosphorylated, serve as recruitment sites for Grb2 as well as
polyproline residues (PP), which serve as binding sites for SH3 domain-containing
proteins (van der Geer et al., 1995; Liu and Meakin, 2002; Rozakis-Adcock et al.,
1992; McGlade et al., 1992; Sato et al., 1997; van der Geer et al., 1996) It has also
been postulated that tyrosine phosphorylation in the CH1 domain serves as a “gate” for
SH2 domain activity due to the fact that the SH2 domain is only active when the three
key tyrosines are phosphorylated (George et al., 2008). Amino acid nominations are
shown below for each domain according to Sakai et al. (2000).
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Shc family members contain two domains for phosphotyrosine binding (Figure 2):
N-Terminal Phosphotyrosine Binding (PTB) and C-Terminal Src Homology 2 (SH2; van
der Geer et al., 1995). They also contain an internal, collagen-homology (CH1) domain,
which contains three target sites for tyrosine phosphorylation by Src and Trk, among
other tyrosine kinases (Y239, 240, and 317 on ShcA); and polyproline motifs which serve
as docking sites for SH3 domain-containing proteins (van der Geer et al., 1995; RozakisAdcock et al., 1992; McGlade et al., 1992; Liu and Meakin, 2002; Sato et al., 1997; van
der Geer et al., 1996). Phosphorylation of the three tyrosine sites upon Trk activation
results in the activation of Ras and MAP kinase signaling through recruitment of Grb2
(Rozakis-Adcock et al., 1992; Figure 1). It has also been shown that phosphorylation of
these three tyrosines is crucial for SH2 domain function (George et al., 2008). Larger
isoforms also contain an N-terminal CH2 domain, containing serines in addition to
polyproline residues, which may be targets for serine phosphorylation, but to date this has
only been investigated in p66ShcA (Xi et al., 2010a). There is also evidence that the
longer isoforms of Shc family members, containing CH2 domains, have opposing roles in
downstream receptor signaling, to their shorter family members. For example, p52 and
p66 ShcA bind competitively to the activated Insulin-Growth Factor Receptor (IGF-1)
and when p66 ShcA is over-expressed we see a reduction in Grb2 recruitment and
downstream signaling resulting in a reduction in cell proliferation (Xi et al., 2008). ShcC
specifically has two isoforms as well, which are 55 and 69 kDa (O’Bryan et al., 1996). As
previously described in section 1.3, the ShcC PTB domain binds to activated TrkB (at
Tyrosine 515), resulting in the phosphorylation of Tyrosine 221, 222, and 304 in the
collagen homology domain and a conformational change in the SH2 domain allowing for
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activity (Liu and Meakin, 2002; George et al., 2008). ShcD, much like other Shc family
members, binds to TrkB and regulates MAPK singling, the exception being that both
PTB and SH2 domains can bind to TrkB (You et al., 2010). George et al. (2008)
generated a non-phosphorylatable mutant (3YF) of ShcA, and showed that its SH2binding capabilities were severely reduced. In addition, a phospho-mimic ShcA was
generated where these same tyrosines were mutated to aspartic acids, and no SH2 binding
was detected, indicating further importance for tyrosine phosphorylation of the CH1
domain in SH2 domain activity. However, mimicking the active state by glutamic acid
substitution may be more beneficial as it contains one extra carbon compared to aspartic
acid, and thus glutamic acid substitution of salient tyrosine residues in ShcC where the
PTB domain is not present (ShcC CH1SH2 3YE) may be useful in studying SH2 domain
function.
ShcC, being an adaptor protein, is expected to have several binding partners.
Upon NGF stimulation in pheochromocytoma (PC12) cells, which express endogenous
TrkA, ShcC is capable of binding to F-actin (Thomas et al., 1995). Through its PTB
domain we see interaction with TrkB (Liu and Meakin, 2002), its CH1 domain with Grb2
(Rozakis-Adcock et al., 1992) and its SH2 domain with epidermal-growth factor receptor
(van der Geer et al., 1995). There is also evidence for ShcC interaction with the NR2B
subunit of the NMDA receptor and Src family kinases upon glutamate stimulation
(Miyamoto et al., 2005). However, interaction with Src family kinases is not clear as this
experiment did not use antibodies specific to any Src family member, and therefore did
not distinguish which protein ShcC was binding to. In addition, they did not include a
negative control (i.e. IgG), nor did they include a Western blot indicating the ShcC
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antibody was correctly immunoprecipitating. Recently, there has been much evidence to
support p66 ShcA binding to Src through its CH2 and SH2 domains in smooth muscle
cells in response to insulin, resulting in an impairment of Src activity and downstream
activation of MAP Kinase and PI3-Kinase (Xi et al., 2010a; Xi et al., 2010b). Taken
together, these studies demonstrate an importance for distinguishing among the Src
family members with respect to ShcC binding, and to elucidate domains of ShcC which
bind to the Src family kinases.
1.5

Glutaminergic Signaling through AMPA and NMDA Receptors.
Synaptic transmission is initiated at the PSD, through neurotransmitter release at

the pre-synaptic terminal, and a resultant electrical impulse in the post-synaptic neuron.
For the purpose of simplicity, only glutaminergic synapses, i.e. those that respond to the
neurotransmitter glutamate, will be discussed. When glutamate is released into the
synaptic cleft, it binds to one of two ionotropic receptors at the PSD: α-amino-3-hydroxy5-methyl-4-isoxazolepropionic acid (AMPA), and N-methyl-D-aspartate (NMDA), which
are permeable to Na+/K2+, and Ca2+ions, respectively (Hollmann et al., 1991; Matsubara
et al., 1996; Xia et al., 1996). AMPA receptors are also permeable to Ca2+, depending on
the subunit composition (Hollmann et al., 1991). The receptors both exist as
heterotetramers, i.e. four non-identical subunits. AMPA receptors may be composed of
different subunit types: GluR1, GluR2, GluR3, and GluR4, with the presence of GluR2
limiting permeability to Ca2+ (Hollmann et al., 1991; Matsubara et al., 1996; Figure 3).
NMDA receptors, alternatively, consist of GluN1/NR1, GluN2/NR2 or the lesser-known
GluN3/NR3 (Al-Hallaq et al., 2007; Henson et al., 2008; Figure 3). Though receptors can
consist of any combination, the presence of NR2A or NR2B is required to produce
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functional receptors (Saito et al., 2003). The subunit composition of these receptors is not
static, and in fact there is a switch in preference from NR2B to NR2A during postnatal
development, likely through an increase in NR2A expression and incorporation into new
synapses (Liu et al., 2004). In addition, NR2A- and B-containing receptors may associate
with different proteins in the PSD (Al-Hallaq et al., 2007). Though not necessarily as
prominent with age, NR2B, but not NR2A receptors are required for LTP: Loss of NR2B
results in learning deficits (Brigman et al., 2010; Foster et al., 2010).

Figure 3. The structure of AMPA and NMDA receptors. Both receptors generally exist
as heterotetramers, composed of either GluR1 and GluR2, or GluN1 (NR1) or GluN2
(NR2) subunits, respectively, shown by convention here as two of each (Hollmann et
al., 1991; Matsubara et al., 1996; Al-Hallaq et al., 2007; Henson et al., 2008). The
functionally relevant subunit on AMPA receptors is GluR1, which determines Ca2+
permeability (Hollmann et al., 1991). The NMDA receptor subunit NR2B is
responsible for regulating internalization of the receptor; when tyrosine
phosphorylated, the internalization process is uncoupled (Roche et al., 2001; Lavezarri
et al., 2003).
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The process of LTP is initiated at the post-synaptic density, by activity changes in
receptors, namely the AMPA and NMDA receptors. NMDA receptors have been
implicated in a number of diseases, including Alzheimer’s disease (Snyder et al., 2005).
NMDA receptor activity is limited by Magnesium; in order for NMDA receptors to
initiate LTP, an Mg2+ block must first be removed (Coan and Collingridge, 1985), though
this process is not very well understood. After NMDA receptors are activated, AMPA
receptors are trafficked to dendritic spines, which may account for an increase in AMPA
receptor activity during LTP (Shi et al., 1999). This is mediated by the GluR1 subunit
binding with PDZ-domain containing proteins (Hayashi et al., 2000), potentially with
PSD-95.
There are many regulators of NMDA receptor activity, but the most prominent is
tyrosine phosphorylation. NMDA receptor activity is modified by both protein tyrosine
phosphatases (PTPs) and protein tyrosine kinases (PTKs), one such tyrosine kinase
implicated in activating the NMDA receptor is c-Src (Wang and Salter, 1994). As
previously stated, there is a marked increase in NR2B tyrosine phosphorylation upon
LTP induction (Rostas et al., 1996), indicating further importance of tyrosine
phosphorylation in learning. In addition, AMPA receptors are also serine/threonine
phosphorylated upon LTP induction, by the calcium-dependent kinase, CaMKII,
implicating both PLCγ and calcium-dependent signaling in LTP (Barria et al., 1997).
BDNF has been shown to increase NMDA receptor activity by indirectly increasing
tyrosine phosphorylation of both NR1 and NR2B subunits of the NMDA receptor (Suen
et al., 1997; Levine et al., 1998; Lin et al., 1998). The BDNF-dependent increase in
NMDA receptor activity can be prevented by blocking the activity of CaMKII (Crozier et
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al., 1999). Src family kinases, Src and Fyn, are also implicated in tyrosine
phosphorylation of both NR2A and NR2B at many sites, in particular Y1472 on NR2B
(Cheung and Gurd, 2001; Nakazawa et al., 2001). Fyn is in fact regarded as the key
kinase in NR2B Tyrosine 1472 phosphorylation (Nakazawa et al., 2001).
NMDA receptors are rapidly turned over by clathrin-mediated endocytosis,
(Roche et al., 2001). In the C-terminal domain of NR2B, there is a YEKL motif that
serves as a binding site for AP-2, an adaptor protein involved in clathrin internalization,
and binding of the PDZ domain of PSD-95 to an adjacent motif effectively blocks
NMDA receptor internalization (Lavezzari et al., 2003; Roche et al., 2001). Tyrosine
1472, in the YEKL motif, is critical for AP-2 binding, as no internalization occurs when
it is changed to an alanine or phenylalanine residue (Lavezzari et al., 2003). It has also
been shown that tyrosine phosphorylation by Fyn at Y1472 increases the number of
NMDA receptors at the cell surface, implicating Fyn in the uncoupling of NMDA
receptor internalization (Prybylowski et al., 2005). Alternatively, NMDA receptors can
be internalized when Y1472 is de-phosphorylated by Striatal-Enriched Protein Tyrosine
Phosphatase (STEP), for example, in response to β-Amyloid (Snyder et al., 2005). STEP
is the key phosphatase in the regulation of NMDA receptor internalization (Braithwaite et
al., 2006). STEP is also responsible for inactivating Fyn, by de-phosphorylating Tyrosine
420 (Nguyen et al., 2002). This leads to the notion that Fyn and STEP have opposing
roles in NMDA receptor regulation (Figure 4).
The Src family of tyrosine kinases consists of many members, three of which are
expressed ubiquitously (Src, Yes, and Fyn), but most important in learning and memory
are Src and Fyn, both of which have been implicated in NMDA receptor regulation
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(Wang and Salter, 1994; Sun et al., 1998; Prybylowski et al., 2005). However, the key
player in NMDA receptor phosphorylation is regarded as Fyn: Fyn mutant mice, but not
Src mutant mice, have impairment in NMDA-dependent LTP and spatial learning (Grant
et al., 1992). Fyn contains both an SH2 and SH3 domain, as well as the kinase (KIN) or
SH1 domain, containing Tyrosine 420 (Superti-Furga et al., 1993; Nguyen et al., 2002).
Fyn, when inactive, is phosphorylated at the C-terminus, Tyrosine 531 in human Fyn, and
is in a folded conformation bound to the SH2 domain (Superti-Furga et al., 1993; Nguyen
et al., 2002). When unphosphorylated at the C-terminus, Src family kinases can be
tyrosine phosphorylated in the kinase domain (Y420 on Fyn), thought to be by
autophosphorylation (Sun et al., 1998). When the activating tyrosine is phosphorylated,
phosphorylation at the C-terminus does not inactivate the protein (Sun et al., 1998). Fyn
is dephosphorylated at Y420, but not 531, by STEP (Nguyen et al., 2002), which would
render it inactive. Fyn is also responsible for mediating BDNF-mediated increase in
NMDA receptor activity, and is also shown to regulate the localization of TrkB receptors
in response to BDNF (Xu et al., 2006; Pereira and Chao, 2007).
Striatal-Enriched Protein Tyrosine Phosphatase (STEP) is, as its name implies,
expressed specifically in the brain and enriched in the striatum (Lombroso et al., 1991).
There are multiple isoforms, arisen by alternative splicing, but the 46 kDa isoform is the
most prominent, with other identified isoforms of 20 and 61 kDa (Lombroso et al., 1991;
Sharma et al., 1995). In addition to the protein tyrosine phosphatase (PTP) domain shared
with STEP46, STEP61 contains two PEST sequences, which may serve as sites for
proteolytic cleavage, two polyproline-rich regions, and two transmembrane domains,
which serve to anchor it to the membrane of the endoplasmic reticulum (Bult et al.,
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1996). Both STEP46 and STEP61, ER-bound, contain a kinase interacting motif (KIM),
necessary for recognizing targets (Nguyen et al., 2002; Paul et al., 2003). STEP61 may be
regulated in some manner by cleavage: there is evidence to support STEP61 being cleaved
by calpain, in response to calcium influx, to a 33 kDa product (Nguyen et al., 1999). The
main function of STEP appears to be regulation of LTP. STEP is a part of the NMDA
receptor complex, and reduces NMDA receptor activity to block or reduce LTP induction
(Pelkey et al., 2002). Upon NMDA receptor calcium-influx, STEP is activated by
calcineurin via dephosphorylation of Serine 221 in the KIM domain (Paul et al., 2003).
This activated form of STEP also serves to regulate the duration of Erk signaling (Paul et
al., 2003). STEP knockout mice are viable and show, not surprisingly, an increase in Erk
phosphorylation (Venkitaramani et al., 2009).

Figure 4. Schematic representation of the opposing roles of STEP and Fyn on NMDA
receptor regulation. Phosphorylation of NR2B Y1472 uncouples internalization of
NMDA receptors by facilitating binding with the PDZ domain of PSD-95 (Roche et
al., 2001; Lavezarri et al., 2003). Fyn, and to a lesser extent Src, are responsible for
phosphorylating NR2B at this site (Prybylowski et al., 2005). Alternatively, STEP is
responsible for dephosphorlating NR2B this site, as well as dephosphorylating Fyn
kinase at its active tyrosine, 416 (Prybylowski et al., 2005; Braithwaite et al., 2006),
allowing for two-tiered regulation of NMDA receptor activity. Furthering this notion,
STEP is responsible for dephosphorylating Fyn at tyrosine 420, rendering it inactive
(Nguyen et al., 2002).
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1.6

The ShcC Knockout Mouse.
In hopes of understanding the function of a protein, scientists often return to the

genetic level and knock out the gene of interest in order to study the consequences. With
many cases, the knockout is not viable, or has a very visible phenotype that gives insight
into the protein’s role. The Shc family members are no exception to this rule. First,
scientists attempted to generate a Shc(A) null mouse to no avail, and it was realized that
this scenario is embryonically lethal, with embryos dying at E11.5 due to large
cardiovascular defects (Lai and Pawson, 2000). A conditional knockout of ShcA in the
subventricular zone (SVZ), the location of neural stem cells, showed irregularities in SVZ
organization, and a reduction in proliferation in the adult brain, which is required to
replenish olfactory bulb interneurons (Ponti et al., 2010). Secondly, ShcB and ShcC
knockouts were generated, as well as a ShcB/C double knockout. ShcB knockout mice
are viable but at 8-9 weeks of age are shown to experience, among other phenotypes, a
~32% reduction in myelenated axons and substantial sensory neuronal loss (~38%) in the
dorsal root ganglion, including a >50% reduction in TrkA+ neurons (Sakai et al., 2000).
The combination ShcB/C knockout mouse demonstrates similar losses to ShcB alone,
indicating a lack of compensation for loss of ShcB by ShcC, while ShcC knockout mice
do not demonstrate any of the aforementioned phenotypes. One population of neurons
affected by the loss of ShcB and ShcC, but not either loss alone, is the sympathetic
neurons of the superior cervical ganglion, where there is a ~33% reduction in the number
of neurons at 8 weeks of age (Sakai et al., 2000).
Surprisingly, ShcC knockout mice have no brain abnormalities or visible neuronal
loss (Sakai et al., 2000). ShcC is expressed highly in the hippocampus, yet loss of ShcC
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does not seem to affect hippocampal morphology (Miyamoto et al., 2005). This led
researchers to examine changes in neural functions, i.e. behaviour, of these mice. In this
respect, the loss of ShcC had a significant impact on the learning and memory
performances of these mice compared to their wild-type litter mates. ShcC knockout mice
have enhanced spatial and temporal memory as shown through the Morris Water Maze
test, improved contextual fear conditioning, and a better visual recognition of novel
objects, all of which are hippocampus-dependent modes of learning (Miyamoto et al.,
2005). Physiologically, ShcC knockout mice demonstrate enhanced hippocampal LTP. At
the molecular level, ShcC knockout mice display an increase in the levels of tyrosine
phosphorylation of the NR2A and NR2B subunits of the NMDA receptor, which
positively correlates with receptor activation, and subsequent LTP (Miyamoto et al.,
2005). It is important to note that antibodies used to detect tyrosine phosphorylation were
not residue-specific, and thus could not identify if NR2B tyrosine 1472 specifically had
been affected. However, there were also no changes in phosphorylation of the Src family
kinases Src or Fyn, at the active site, and an in vitro Src activation assay showed no
changes in Src kinase activity (Miyamoto et al., 2005).
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1.7

Hypothesis
ShcC binds to Fyn through its CH2 and SH2 domains and prevents its activity,

allowing for regulation of NR2B Tyrosine 1472 phosphorylation. ShcC knockout mice
would thus have an increase in NR2B tyrosine phosphorylation because of increased
availability of Fyn kinase.
1.8

Objectives
a.

To determine if ShcC can bind to Fyn and/or Src.

b.

To determine the domains of ShcC involved in interaction with Fyn or Src in
vitro.

c.

To determine if tyrosine phosphorylation of the ShcC CH1 domain is important
for Fyn and Src binding in vitro.
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Chapter 2. Materials and Methods
Note: For a full listing of all solutions named below, please see Appendix I.
2.1

DNA Cloning, Extraction and Purification
a.

Site-directed mutagenesis.

The reference protocol for site-directed mutagenesis was obtained in the
QuickChange-XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The
intention was to introduce three tyrosine to glutamic acid substitutions at the three
tyrosine sites in mouse ShcC (Y221, 222, and 304) that are involved in downstream
signaling through Grb2 (Figure 5). The rationale for changing three tyrosine sites in the
CH1 domain to glutamic acids was to create a mutant that carries a negative charge at
these sites, and is more likely to adopt the correct conformation and potentially allow for
constitutive binding in the absence of activation by Trk. These mutations were introduced
in a ShcC GST fusion construct containing only the CH1 and SH2 domains (pGEX ShcC
CH1SH2), to investigate SH2 binding partners in the absence of the PTB domain to
confound data. Briefly, circular DNA was amplified using a primer set that was
complementary and contained the mutation of interest in the middle (Table 1) and
PfuTurbo, a high-fidelity Taq polymerase enzyme supplied with the kit. Briefly, 1-5µL of
template DNA and 125ng of forward and reverse primer were incubated with 200µM
dNTPs, 1X concentration of PfuTurbo buffer, and 2.5U PfuTurbo in the conditions
outlined in Table 2. Following PCR amplification, parental DNA was digested with
DpnI, a methylation-specific frequent cutting restriction enzyme by addition of 1µL
(10U) to the PCR product and a1 hour incubation at 37ºC. Following digestion, 1µL of
the amplified DNA was transformed into 100µL XL10-Gold, a cloning strain of E. coli
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provided in the kit, using 100µg/mL Ampicillin selection as described below (b).
Colonies were selected; DNA was prepared and sequenced as described below (c) to
screen colonies for the mutation of interest. In addition, the native vector (pGEX ShcC
CH1SH2) was co-expressed with pET28a V-Src to allow for tyrosine phosphorylation at
these sites.
Table 1. List of primers used to introduce Y221E, Y222E, and Y304E mutations into
ShcC.
Mutation
Y221E

Y222E*

Y304E

Sequence (5’-3’)

Tm

Forward ATGGCCCTGATCACCCAGAATACAACAGCGTTCCCAC

83.9

Reverse GTGGGAACGCTGTTGTATTCTGGGTGATCAGGGCCAT

83.9

Forward ATGGCCCTGATCACCCAGAAGAAAACAGCGTTCCCAC

84.4

Reverse GTGGAACGCTGTTGTATTCTTCGTGATCAGGGCCAT

82.7

Forward GTAGGAGAAACACCAACCGAGGTCAACACCCAGCCAG
TCCC

85.7

Reverse GGGACTGGCTGGGTGTTGACCTCGGTTGGTGTTTCTCCT
AC

85.7

Note: Nucleotides designed to introduce mutations are underlined. Y222E Primers (*)
were designed for a template with the Y221E mutation completed. Tm values are given
in ºC.
Table 2. PCR conditions for site-directed mutagenesis.
30 Cycles
95ºC
1:00

95ºC

55ºC

68ºC

0:30

1:00

20:00

Hold
4ºC

Note: Extension time was meant to be at least 1 minute per kb of plasmid DNA.
Extension temperature of 68ºC was indicated by PfuTurbo (Stratagene).

25

b.

Making Competent Cells and Transformation

Rubidium Chloride competent E. coli were prepared using a protocol adapted
from the McManus Lab (University of California San Francisco, San Francisco, CA). A
3mL LB culture inoculated with the BL21-DE3 strain under 25µg/mL chloramphenicol
selection was grown overnight at 37ºC with constant agitation. The following day, the
culture was transferred over to a 50mL LB flask and grown under the same selection to
an OD600 of approximately 0.6. Then, cells were centrifuged at 5000xg for 10 minutes in
a Beckman JA-20 rotor, and the pellet rinsed with a small amount of TFBI to remove
excess media. Then, the cells were re-suspended in 20mL transformation buffer I (TFBI;
100mM Rubidium chloride, 50mM Manganese chloride, 30mM Potassium acetate,
10mM Calcium chloride, and 15% glycerol) by repeated pipetting and placed on ice for 5
minutes. Next, the cell suspension was centrifuged at 5000xg for 5 minutes in a Beckman
JA-20 rotor. The resultant pellet was re-suspended in 2mL of TFBII (10mM MOPS,
10mM Rubidium chloride, 75mM Calcium chloride, and 15% glycerol) and placed on ice
for 15 minutes. The resultant suspension of competent cells was separated into 200µL
aliquots, which were flash frozen in liquid N2 and stored at -80ºC prior to use.
On the day of transformation, the desired amount of DNA (typically 1-5µL) was
mixed with 100-200µL of competent cells prepared as described above. This reaction was
mixed by pipetting and allowed to incubate on ice for 30 minutes. Next, transformations
were given a 45 second heat shock at 42ºC, and placed briefly back on ice. For recovery,
0.5-1mL of LB was added to the transformation and tubes were placed at 37ºC with
constant agitation for 1 hour. Transformations were then centrifuged at 1520xg in the IEC
Micromax centrifuge for 1 minute, to sediment cells, media was decanted minus
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approximately 100µL and the remainder was re-suspended, plated on LB agar plates
containing the appropriate selection pressure (100µg/mL Ampicillin and/or Kanamycin)
and allowed to incubate overnight at 37ºC. Individual colonies were selected the
following day for further experimentation.
c.

DNA Extraction and Purification

Bacteria containing the vector of interest were first grown overnight in 3mL or
50mL LB media, under the appropriate selection measure (100µg/mL Ampicillin for
pGEX and pEBG vectors, or Kanamycin for pET28a vectors), and centrifuged at 3901xg
in the Beckman coulter Allegra X-22R centrifuge for 10 minutes to pellet cells. For a
small-scale DNA extraction, pellets were placed on ice and re-suspended in 100µL
Solution I (2.5mM Tris-Cl pH 8.0, 10mM EDTA, 50mM glucose) by pipetting and
transferred to a 1.5mL microcentrifuge tube. Next, 200µL of Solution II (1% SDS,
200mM NaOH) was added and samples were inverted 3-5 times. In the same manner,
175µL of Solution III (3M Potassium acetate, 1.18M Acetic Acid) was added. Next,
500µL buffer-saturated phenol:chloroform (BioShop) was added, and samples were
vortexed until opaque. Samples were centrifuged at 10,621-20,817xg in the Eppendorf
5417R centrifuge for 15 minutes to separate the aqueous and organic phases. The upper,
aqueous

phase

was

transferred

to

a

fresh

tube

and

washed

with
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Choloroform:Isoamyl alcohol and centrifuged again as described above to separate
phases. To precipitate DNA, 1mL of 100% ethanol was added and samples were left at
room temperature until a DNA precipitate was visible, approximately 10-30 minutes. The
DNA was pelleted by centrifugation at 10,621-20,817xg in the Eppendorf 5417R
centrifuge for 15 minutes, washed once with 70% ethanol, and once with 100% ethanol,
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centrifuging for only 5 minutes. The DNA samples were left to dry, and re-suspended in
50µL TE. If sequencing, samples were treated with 1µL RNAse and incubated at 37ºC
overnight. The following day, DNA was re-extracted by the addition of 150µL H2O and
200µL Phenol:Chloroform and centrifuged as described above. The aqueous phase was
transferred to a fresh tube and washed with 200µL Chloroform:Isoamyl as described
above. DNA was precipitated by the addition of 20µL 3M Sodium Acetate (pH5-6) and
450µL 100% ethanol, and was placed on ice for 0.5h. Samples were centrifuged at
10,621-20,817xg as previously described and the DNA pellet was washed with 70% and
100% ethanol again. Dried pellets were re-suspended in 50µL TE and 5µL was run on an
agarose gel to verify purity and approximate concentration. To be sequenced, 10µL
DNA, or DNA made up to 10µL with TE, was mixed with 5µL sequencing primer (GST
Sequencing primer, indicated in pGEX vector map, was used for pGEX and pEBG;
pET28a was sequenced using the T7 primers provided by the facility) and sent to the
Robarts Sequencing Facility to be sequenced. Electropherograms were obtained and
analyzed afterwards.
For a large-scale DNA extraction, bacterial cultures grown in 125mL Erlenmeyer
flasks were transferred to 50mL conical tubes prior to centrifugation. Pellets were placed
on ice and re-suspended in 10mL Solution I by repeated pipetting. Next, 10mL of
Solution II was added and samples were inverted 3-5 times. In the same manner, 5mL of
Solution III was added. Next, 10mL buffer-saturated phenol:chloroform (BioShop) was
added, and samples were vortexed until opaque. Samples were centrifuged at 3901xg in
the Beckman Coulter Allegra X-22R centrifuge for 15 minutes to separate the aqueous
and organic phases. The upper, aqueous phase was transferred to a fresh tube and DNA
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was precipitated using, 15mL of isopropanol. Successfully extracted DNA was visible as
large, cotton-like white strings, and was subsequently centrifuged at 3901xg in the
Beckman Coulter Allegra X-22R centrifuge to pellet DNA. Pellets were left to dry and
re-suspended in 1mL TE. Exactly 1.08g of CsCl2 was weighed out and dissolved in the
DNA:TE mixture. DNA was visualized by the addition of 20µL Ethidium Bromide
(10mg/mL). Samples were spun at 20,817xg in the Eppendorf 5417R centrifuge for 3
minutes to remove any residual protein which appears very dark. Next, the DNA:CsCl2
mixture was transferred to a plastic ultracentrifuge tube (Beckman Polyallomer QuickSeal Centrifuge tubes, 8x35mm) sealed using a tube topper, while checking for air
bubbles and leaks. Tubes were placed in a Beckman TLN120 rotor and centrifuged at
448804xg for 1.5h. The CsCl2 forms a gradient, and circular plasmid DNA presents as a
large pink band in the centre of the gradient under ambient light, which is then extracted
using a syringe and transferred to a fresh 1.5mL microcentrifuge tube. Ethidium bromide
was removed by washing with an equal volume of H2O-saturated butanol and centrifuged
at 20,817xg as previously described for 3 minutes. DNA went into the aqueous phase
while ethidium bromide went into the butanol-rich phase (less dense, upper phase). The
upper phase was removed and the DNA was washed repeatedly until both the top and
bottom phases were clear. DNA was re-precipitated in 2.5 volumes 70% ethanol at room
temperature. Samples were washed once with 70% and once with 100% ethanol, allowed
to dry, and re-suspended in 100µL TE. DNA was then assessed by spectrophotometry
using a NanoDrop (Thermo Scientific) hosted by the Cregan Lab at Robarts Research
Institute. Both the concentration (in µg/mL) and the A260/280 ratio were noted, and then
DNA was diluted to desired concentration (typically 1µg/µL) for use.

29

d.

DNA Cloning, Digestion and Ligation

For cloning of new vectors, insert DNA was made by PCR amplification from
full-length mouse ShcC obtained from Dr. Tony Pawson’s laboratory (Samuel Lunenfeld
Research Institute, Mt. Sinai Hospital, Toronto; pcDNA ShcC Full Length) and both the
amplicon and vector DNA were digested with the same two restriction enzymes, allowing
for ligation in the correct orientation. All ShcA and ShcC domains (Figure 5) were cloned
consistent with the domain breakdown done by Sakai et al (2000). The ShcA CH2
domain was amplified from full-length ShcA cDNA prepared from a small-scale DNA
extraction using 40ng of the primers 5’-GGTT GGATCC ATG AAC AAG CTG AGT
GG-3’ (BamHI site in bold, Tm=74.4ºC) and 5’- CCTG GCGGCCGC CTA TTT GTC
GTT GGG ATG CAG -3’ (NotI site in bold, stop codon underlined, Tm=87.3ºC),
incubated with 200µM dNTPs,

1X concentration of PCR buffer and 1mM MgCl2

provided with Taq, and 2.5U Taq (Invitrogen) and the thermocycler conditions outlined
in Table 3. The ShcC CH2 domain was cloned similarily using the primers 5’- TGGATT
GGATCC

ATGAGTGCCACCAGGAAGAGCCGGGCC

-3’

and

5’-

CAGA

GCGGCCGC TCA CAC CTG ATC GCT GGT GTG CGG CGC -3’ (Tm=90.2 and
95.4ºC, respectively), and ShcC CH1 was cloned using 5’- GGTT GGATCC CAG TGC
CCT TCC AAG GTT CC -3’ and 5’- CCTG GCGGCCGC CTA AGC GTT AAG CTC
CTC CAG -3’(Tm=81.0 and 85.2ºC, respectively). It is important to note that the
predicted size of ShcC CH2 (approx. 3 kDa) does not account for the change in protein
size between p55 and p69 ShcC (14 kDa), likely due to upstream DNA sequence that had
yet to be identified when the cDNA was cloned out of mouse. In addition, V-Src was
PCR-amplified using the primers 5’- TT GCGGCCGC C ATGGGGAGTAGCAAG -3’
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(NotI site in bold, Tm=82.7ºC) and 5’- TTA CTCGAG CTA CTCAGCGACCTCC -3’
(XhoI site in bold, stop codon underlined, Tm=69.5ºC).The desired amount of insert DNA
amplified by PCR (typically 3-5µL) and vector backbone DNA (pEBG and pGEX 4T1for ShcC vectors, pET28a for V-Src, typically 5µL) was combined with 3µL of the
correct restriction enzyme buffer, 3µL of 1mg/mL BSA (Fermentas; 0.1mg/mL final
concentration) if not already in the buffer, and 1µL (5U) total restriction enzyme
(BamHI, NotI, or XhoI; Fermentas) in a final volume of 30µL (with H2O). For digestion
with two enzymes, the most compatible restriction enzyme buffer was used and 0.5µL
(2.5U) of each restriction enzyme. Digestions were allowed to proceed overnight at 37ºC.
Table 3. PCR conditions for DNA cloning.
30 Cycles
95ºC
1:00

95ºC

55ºC

72ºC

0:30

1:00

20:00

Hold
4ºC

Note: Extension temperature of 72ºC was indicated by Taq enzymes (Invitrogen).

The following day, digestions were run out on an agarose gel and desired bands of the
correct size were excised and purified using the QiaQuick Gel Extraction Kit taking
precautions to increase DNA yield. Briefly, bands were excised into 3 volumes buffer
QG and heated in a 50ºC water bath until no gel slice was visible, and one volume of
isopropanol was added. The samples were transferred to a spin column and allowed to
incubate for 5 minutes at room temperature, allowing DNA to bind to the membrane, and
then centrifuged at 15,700xg in the Eppendorf 5415D centrifuge for 1 minute. Next, the
membranes were washed with 0.5mL buffer QG to remove excess agarose, and spun
again for 1 minute at 15,700xg in the Eppendorf 5415D centrifuge. The DNA bound to
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the membrane was then washed with 0.75mL buffer PE, and allowed to incubate at room
temperature prior to centrifugation at 15,700xg in the Eppendorf 5415D centrifuge for 1
minute. This wash was repeated to remove the extra salt. Once the second wash was
completed, the spin column was centrifuged at 15,700xg as previously described for 1
minute, rotated 180º, then centrifuged again to remove any liquid from the membrane.
Then, DNA was eluted by adding 30µL of elution buffer provided with the kit (buffer
EB) which had been warmed to 37ºC and a 5 minute incubation at room temperature.
DNA was removed from the membrane by placing the upper portion of the spin column
in a fresh 1.5mL microcentrifuge tube and centrifuging this at 15,700xg for 1 minute,
allowing it to incubate for one minute, and repeating the spin. Purified DNA was then
used in ligation reactions.
To ligate compatible end fragments, 1µL of plasmid DNA was combined with an
excess of insert DNA (typically 4µL), 1.5µL 10mM ATP, 1.5µL ligation buffer, and 1µL
T4 DNA ligase in a final volume of 15µL with H2O. A control ligation was also set up,
using 4µL H2O in place of insert DNA. The reaction was allowed to proceed at 4ºC
overnight and ligations were directly transformed into XL-10 gold strain of E. coli.
Colonies were selected, DNA was extracted, and insert was verified by DNA sequencing
as described above.
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Figure 5. Schematic representation of all ShcC vectors manipulated in 2.1.a (A) and 2.1.d (B), and
used for GST pulldown experiments either in HEK 293T cells (2.2) or expressed and purified from
bacteria and incubated with mouse brain lysate (2.5), with protein sizes shown in brackets. Domain
breakdowns were setup according to Sakai et al. (2010) and cloned from a full-length ShcC cDNA
obtained from Dr. Tony Pawson’s laboratory (Samuel Lunenfeld Research Institute, Mt. Sinai
Hospital, Toronto). Note: Constructs denoted with an asterisk were previously cloned by former lab
members Ian Grant (pEBG and pGEX ShcC CH1SH2 and ShcC SH2, and pEBG ShcC PTB) or
Hui-Yu Liu (pGEX ShcC PTB).
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2.2

Cell Culture and DNA Transfection

Note: For a full listing of all vectors named below, please see Appendix I, Table I.
All cell cultures were incubated in a 37ºC incubator with 5% CO2 and constant
humidity. All passages, transfections, and media changes were completed in a HEPAfiltered biological cabinet. Primarily, the HEK 293T cell line was used, which required
passing every 3-4 days to avoid overgrowth and senescence. Standard HEK 293T media
was used for preparation: Dulbecco’s Modified Eagle Medium (DMEM; Wisent), 10%
Fetal Bovine Serum (FBS; Wisent), and 50µg/mL Gentamycin sulfate (Wisent).
Transfections were originally carried out through the calcium phosphate method.
Briefly, cells were plated at approximately 500,000-750,000 cells per 10cm dish in order
to have cells at 50-60% confluency the day of transfection. Cell media was changed 1-2
hours prior to transfection. Desired amount of DNA was dissolved in 450µL water: 2.5µg
pcDNA 4/T.O. Fyn(1-536)-GFP (Naoto Yamaguchi; Kasahara et al., 2007) and 5µg
pEBG(-), ShcA CH2, ShcC CH2, PTB, CH1, or SH2, and 50 µL 2.5mM CaCl2 was
added drop-wise to the mixture. Next, 450 µL of 2XHBSS (See Appendix I) was added
drop-wise and the reagents were mixed by pipetting up and down, passing air through the
mixture. The transfection mixture was added drop-wise to the plates and allowed to
incubate overnight, and media was replaced the next day. Cells were lysed 48 hours later
and subject to further experiments. To reduce cytotoxicity with over-expression of FynGFP, the amount was reduced to 1µg, and after optimization for low transfection
efficiency a switch to Lipofectamine- 2000TM (Invitrogen) transfection was used.
For Lipofectamine-2000TM transfection, cells were also plated to reach 50-60%
confluency for use. Approximately 1 hour prior to transfection, media was changed and
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reduced to a volume of 4mL to increase the concentration of reagent. For each plate, two
1.5mL microcentrifuge tubes were aliquoted with 0.5mL Opti-MEM (Invitrogen)
transfection media. To one tube for each plate, 1µg of pcDNA 4/T.O.Fyn(1-536)-GFP,
pcDNA 4/T.O. Src(1-532)-GFP (Naoto Yamaguchi, Kasahara et al. 2007), or pCMV5 CSrc (Joan Brugge via Addgene) and 5µg of one of pEBG (-), ShcA CH2, ShcC CH2,
PTB, CH1, or SH2 were added and allowed to incubate. Note: there was more success
transfecting pEBG ShcC CH1 when reduced to 2.5µg. To the second tube, 10µL of
Lipofectamine was added and allowed to incubate for 5 minutes. One tube of each DNA
and Lipofectamine were combined and allowed to incubate for 20 minutes. The
DNA:Lipofectamine mixture was added drop-wise to plates and allowed to incubate
overnight. Media was replaced the following day, to 10mL, and plates were lysed for
experiments 24-48 hours after transfection, dependent upon cell density and transfection
efficiency.
2.3

Cell Lysate Preparation
a.

From CD-1 Mouse Brain Lysates

Standard NP-40 lysis buffer (see Appendix I) was prepared, containing 1mM
Sodium orthovanadate (Sigma-Aldrich), 1mM PMSF (Sigma-Aldrich) and 10µg/mL each
Aprotinin and Leupeptin (Bioshop). Mice were euthanized according to the procedures
outlined in animal protocol #2009-048 according to standard operating procedures: Mice
under post natal day 21 (P21) were euthanized by decapitation, mice P21 and older were
euthanized by CO2 asphyxiation. Mouse brains were dissected into the aforementioned
NP-40 lysis buffer and lysed by needle shearing, with needles increasing in gauge (18-2225). Samples were incubated on ice, and centrifuged at 20,817xg in the Eppendorf 5417R

35

centrifuge 10 minutes to remove insoluble materials. A second spin was added if
necessary. The protein-containing supernatant was saved, and subject to protein
determination for experiment, using the BioRad DC Protein Assay.
b.

From HEK 293T Cell Lysates

Lysis buffer was prepared using Interaction Buffer (IB, see Appendix I) and 1mM
Sodium orthovanadate, 1mM PMSF and 10µg/mL Aprotinin and Leupeptin. Prior to
lysis, dishes were washed on ice with cold PBS to remove all traces of media. Next, cells
were scraped off into 500µL IB into a 1.5mL microcentrifuge tube and incubated on ice
for 5-15 minutes, vortexing intermittently until all chunks of tissue disappeared. Any
plates where cells had begun to detach were lysed similarly, but media was also collected
from the dish and spun at 3901xg in the Beckman coulter Allegra X-22R centrifuge to
sediment cells for lysis. Cells were then centrifuged at 20,817xg in the Eppendorf 5417R
centrifuge 10 minutes to remove all insoluble components. Supernatants were saved in a
fresh tube and subject to protein determination and further experiments. If the insoluble
pellet was also saved for experiment, it was re-suspended in 200µL of the same buffer
and further lysed by sonication. Samples were quantified as described above.
2.4

GST Fusion Protein Preparation

Note: For a full listing of all vectors named below, please see Appendix I, Table I.
For pGEX 4T vector expression (GST, GST-ShcA CH2, GST-CH2, GST-PTB,
GST-CH1, GST-SH2, and GST-p55 ShcC) vectors were left in the original, cloning
strain (DH5α, XL-10 Gold). When pGEX 4T vectors (GST, GST-CH1, GST-CH1SH2,
and GST-CH1SH2 3YE) were co-expressed with pET28a or pET28a V-Src, vectors were
co-transformed into the BL21-DE3 strain to allow for proper expression. Bacterial
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cultures were inoculated and grown to an OD600 of 0.8-0.9, and induced with 1-2mM
IPTG for 2h. Following induction, cells were pelleted at 3901xg in the Beckman coulter
Allegra X-22R centrifuge for 15 minutes. Cell pellets were stored at -80ºC until
purification. Pellets were re-suspended in PBS containing 2mM EDTA, 1mM PMSF and
Sodium orthovanadate, and 10µg/mL Aprotinin and Leupeptin (PBS Lysis I) and lysed
by sonication. Triton X-100 was added to the lysate, at 1% final v/v, and samples were
incubated at 4ºC with constant rotation of 0.5-1h. The lysate was centrifuged at 26832xg
for 15 minutes in a Beckman JA-20 rotor and supernatant saved to a fresh tube. Fusion
proteins were purified by the addition of washed (with PBS) glutathione-agarose beads,
incubated overnight. If fusions were purified alongside pET28a, they were incubated for
2h, to avoid phosphorylation decay. GST fusion proteins were then washed 7-10 times
with PBS containing 1% Triton X-100, 2mM EDTA, 1mM PMSF and Sodium
orthovanadate, and 10µg/mL Aprotinin and Leupeptin (PBS Lysis II) and stored at 0ºC
bound to glutathione-agarose. Protein concentration was estimated by running 10, 20, and
40µL of the fusion protein alongside 1, 2, and 4µg of BSA on a polyacrylamide gel and
staining with Coomassie Blue. The advantage of visualizing GST fusion proteins was
also being able to assess purity and any possible degradation.
2.5

GST Pulldowns
Once protein quantity and quality assessment of purified GST fusion proteins

were completed, GST fusion proteins were incubated with quantified mouse brain lysate
(see above) at a ratio of 2µg fusion protein to 3-5mg protein, preferably 4, overnight at
4ºC with constant rotation. The following day, pulldowns were washed 5-8 times at
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3901xg in the Beckman Coulter Allegra X-22R centrifuge, for 3-5 minutes and stored at 20ºC in sample buffer prior to SDS-PAGE.
2.6

Immunoprecipitation

Note: For a full list of antibodies used in immunoprecipitations, see Appendix I, Table II.
Immunoprecipitation (IP) was carried out in a similar manner to GST pulldowns.
Protein-G-Sepharose (Gammabind; GE Life Sciences) was washed in NP-40 lysis buffer
and 25µL of 50% Gammabind:NP-40 was incubated with 3-5mg quantified mouse brain
lysate (see above) and1-2µg primary antibody overnight at 4ºC with constant rotation.
Antibody concentrations were determined empirically in addition to product information
sheets provided by suppliers and are listed in Appendix I. The following day, IPs were
washed 3-5 times at 2655-10,621xg in the Eppendorf 5417R centrifuge for 3-5 minutes
and stored at -20ºC in sample buffer prior to SDS-PAGE.
2.7

SDS-PAGE and Western Blotting

Note: For a full list of all antibodies used in Western Blotting, see Appendix I, Table II.
Polyacrylamide gels were prepared in two parts according to previously outlined
methods in our laboratory (Grant, 2009): a lower gel for sample resolution, and an upper,
stacking gel for well creation.The correct volume of 30% Acrylamide/Bisacrylamide for
the desired percentage (3.3mL for 10%, 2mL for 7.5%) was combined with 2.5mL Lower
Tris buffer, H2O to 10mL, 50µL 10% Ammonium Persulfate (APS) and 7.5µL TEMED
(BioShop). To straighten the edge of the gel, 1mL of 100% ethanol was over-layed.
When polymerized, the ethanol was washed away with water and area was blotted dry
with blotting paper. The upper gel was prepared using 2.5mL Upper Tris, 1.3 mL 30%
Acrylamide/Bisacrylamide (4% gel), 6.2mL dH2O, 50µL 10% APS and 7.5µL TEMED,
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and over-layed on the lower gel, and a 10-well or 15-well comb was inserted. When set,
the gel was loaded into the rig and flooded with SDS-PAGE buffer.
Prior to sample loading, all samples were boiled at 65ºC for 10 minutes and
placed on ice. Pulldowns and IPs were centrifuged at 20,817xg in the Eppendorf 5417R
centrifuge for 3 minutes to pellet beads. Samples were loaded into the wells, with lane 1
typically containing 10µL PrecisionPlus Dual Colour Protein Molecular Weight
Standards (BioRad) as a size indicator. Gels were resolved at 200V for 30-40 minutes,
until the dye front approached the bottom of the gel. Afterwards, gels were either stained
with Coomassie Blue, or proteins were transferred onto PVDF membranes using a semidry transfer apparatus. Briefly, a labelled 0.2µm PVDF membrane (Bio Rad) was wet
with methanol and soaked in transfer buffer, along with two pieces of blotting paper. The
gel was popped out of the glass slides and placed on top of blotting paper in the semi-dry
apparatus, smoothing out any air bubbles. Next, the PVDF membrane was placed on top
of the gel, smoothing out any bubbles, and the second piece of blotting paper. The
apparatus was run at 0.5A for 1-2h, depending on the gel percentage and target protein
size.
When removed, protein molecular weight marker was visible on the membrane as
pink and blue bands on the left hand side. Membranes were blocked with either 10%
Milk-TBS-Tween, or BSA-TBS-Tween with 100µM Sodium orthovanadate, for 1h at
room temperature and primary antibody was added at the correct dilution, typically
1:2000, determined empirically, and allowed to incubate at 4ºC overnight. Note: For a
full list of all antibody dilutions, please see Appendix I. The next day, blots were washed
4-6 times with TBS-Tween and secondary antibody (1:10,000 HRP-coupled Goat anti-
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Mouse or Goat anti-Rabbit; Jackson Laboratories) was added in new blocking buffer for
1h at room temperature. Secondary antibody was washed in the same manner as primary,
and blots were visualized using the ImmunStar WesternC Kit (BioRad) on a Chemi-Doc
using the ImageLab software version 3.0 (Beta) provided with the Gel Doc. Signal
quantifications were carried out by determining the relative band intensity of each lane to
a selected reference band (designated 1.00).
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Chapter 3. Results
3.1

ShcC and STEP are expressed at varying levels in development, while Fyn

Remains Constant
First, I sought to assess the developmental expression levels of ShcC, STEP, and
either Src or Fyn, both of which are ubiquitously expressed proteins (Sun et al., 1998).
STEP was also considered a potential binding partner for ShcC at this time. Since Fyn is
the primary player in NMDA receptor regulation (Nakazawa et al., 2001), I selected Fyn
rather than Src for this experiment. The purpose was not only to verify literature on
protein expression in different mouse strains to CD-1 mice, but to select an appropriate
age for co-immunoprecipitation studies. To elucidate the protein levels of ShcC and
STEP during postnatal development, and the age at which protein levels are most
abundant, cortices were taken at different ages of CD-1 mice and 50µg of whole cell
lysate was run on a 10% polyacrylamide gel and blotted either for mouse-anti ShcC
(BD); mouse-anti STEP (Santa Cruz Biotechnology); or mouse-anti β-actin (Sigma) as a
protein loading control. Fyn levels during development were similarly determined in
whole mouse brain with mouse-anti Fyn (Abcam). As shown in Figure 6, ShcC protein
levels were not static. Both isoforms seem to rise after birth, are clearly detectable at P7
and peak at around P21 (Figure 6). STEP, similarly, seems to be more abundant
postnatally, being detectable at P7 and peaking around P21 (Figure 6). Thus, mice at the
ages of P7 and P21 were used for further studies. Fyn levels, as previously reported (Sun
et al., 1998), remain relatively constant (Figure 7A). It is important to note, however, that
with several Western Blots, I was not able to generate data where β-actin levels were
constant. Next, I compared the relative band intensity of Fyn to actin at each age, and
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found that the intensity of the Fyn signal ranged from 0.76 to 1.38 times that of actin
(Figure 7B). Though several attempts were made, with fresh samples, it was concluded
that, as Fyn levels remained comparable to actin at each age, that Fyn levels were likely
constant. This was performed only to verify what was published in the literature (Sun et
al., 1998) and was not attempted any further.

Figure 6. Developmental expression analyses of ShcC and STEP in CD-1 cortices,
using 50 µg whole-cell lysate (WCL). ShcC presents as two isoforms, of 55 and 69
kDa; while STEP presents as two isoforms of 46 and 61 kDa. Western Blots were
carried out with 1:5000 mouse-anti ShcC, 1:2000 mouse-anti STEP, and 1:10,000
mouse-anti β-actin. N=2.
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Figure 7. Developmental expression analysis of Fyn in CD-1 whole brain lysates. A)
Western Blots were carried out with 1:5000 mouse-anti Fyn (59 kDa) and 1:10,000
mouse-anti β-actin. N=2. B) Relative band intensity of Fyn to the corresponding βactin band for each mouse age was determined utilizing the relative intensity function
of Image lab software. N=1.
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3.2

ShcC Co-Precipitates with Fyn and Src, but not with STEP
Previously in our lab, ShcC was shown to weakly co-immunoprecipitate with

STEP from mouse brain lysates (Grant, 2009) though this result was not consistent. This
indicated a potential interaction between ShcC and STEP. Here, the association of ShcC
and STEP was re-investigated using 2-4 mg of brain lysate from CD-1 mice. In addition,
association of ShcC with two Src family kinases, Src and Fyn, was similarly investigated.
Co-immunoprecipitations (co-IPs) were carried out using mouse-anti ShcC, mouse-anti
Fyn, rabbit-anti ShcC (Santa Cruz Biotechnology), rabbit-anti Src (Cell Signaling) and
rabbit-anti STEP antibodies (Cell Signaling), with normal mouse IgG (Millipore) and
rabbit IgG’s (Santa Cruz Biotechnology) serving as negative controls. As shown in
Figure 8 (A,B), immunoprecipitation of Fyn indicates a interaction with the lower (p55)
but not the upper (p69) isoform of ShcC at both P7 and P21. This co-IP is not considered
background as the relative band intensity is higher than that of mouse IgG (Figure 8D).
Similarly, as shown in Figure 9A, the p55 isoform of ShcC was shown to co-IP with Src,
yet a co-IP was also observed with p69 ShcC and Src (Figure 9A). This co-IP is also
considered above background as the relative band intensity is higher than that of mouse
IgG (Figure 9D). In addition, both Fyn and Src antibodies were found to successfully
precipitate their target proteins (Figure 8C, and 9A). Two replicates of each co-IP were
shown to circumvent minor imperfections in each blot which, after several repetitions, I
was not able to remove. Most importantly, I was not able to rid Western Blots of the IgG
heavy chain band (50 kDa) when I immunoprecipitated and blotted with mouse
antibodies (Figure 8). I attempted to change both primary and secondary antibodies to
different species, but doing so destroyed the co-IP signal. The interaction between ShcC
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and Fyn or Src was albeit weak, however the results did support my hypothesis that ShcC
could bind to Fyn. The absence of interaction between p69 ShcC and Fyn or Src could be
due to the fact that p69 ShcC is much less abundant (Figure 6). However, this warrants
further investigation as published literature has demonstrated that full-length ShcA can
bind to Src (Xi et al., 2010a). To further address this, a subdomain approach was taken in
section 3.3 to determine if the CH2 domain, present only in p69 ShcC, is capable of
pulling down Src or Fyn, with the notion that if the CH2 domain is capable of binding,
the full-length 69kDa protein has the potential to bind. In addition, after several attempts,
I was unable to replicate any data to suggest that ShcC co-immunoprecipitated with
STEP, and therefore concluded that ShcC interaction with STEP was unlikely (Figure
9B). However, I was able to verify the STEP antibody was immunoprecipitating its target
(Figure 9C).
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Figure 8. ShcC co-immunoprecipitatation studies with Fyn in both P7 and P21 whole brain
lysates. A) and B) P7 and P21 mouse whole brains were used to precipitate with both mouse-anti
Fyn and mouse-anti ShcC. As a positive control, 50µg of the same whole brain (cell) lysate
(WCL) was loaded in the first lane. Both Mouse IgG and mouse-anti Fyn lanes were loaded with
relative fractions representative of 1mg IP from brain lysate, mouse-anti ShcC lanes were loaded
with half of that value (0.5mg) to prevent antibody saturation during Western Blotting. Western
Blots were carried out with 1:2000 mouse-anti ShcC. Note: An asterisk (*) is placed to the left of
a band indicating a successful co-IP. N>3. C) Fyn was immunoprecipitated in the same manner
as (A) and (B), and 1mg representative fraction was loaded with Western Blots being carried out
with 1:2000 mouse-anti Fyn. N=2. D) Quantification of relative band intensity of p55 ShcC, for
(A) and (B) using Mouse IgG as a reference, was carried out using Image lab software.
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Figure 9. ShcC co-immunoprecipitatation studies with Src and STEP in P7 and P21
whole brain lysates. A) P21 mouse whole brain lysates were used to precipitate with
rabbit-anti ShcC, rabbit-anti Src and/or rabbit-anti STEP. As a positive control, 50µg of
the same brain lysate was loaded. Samples were loaded with volumes representative of
1mg IP from brain lysate. Western Blots were carried out with 1:2000 mouse-anti ShcC
and 1:2000 rabbit-anti Src. Western Blotting for Src yields a band of 60 kDa. Note: An
asterisk (*) is placed to the left of a band indicating a successful co-IP. N=3. B) P7
mouse whole brains were used to precipitate with rabbit-anti ShcC and rabbit-anti
STEP, with Western Blots were carried out as described in (A). N>3. C)
Immunoprecipitation of STEP, in the same manner as (B). Western Blotting was carried
out with 1:2000 mouse-anti STEP. N=1. D) Quantification of relative band intensity of
p69 ShcC (A) and p55 ShcC(A and B), using Rabbit IgG as a reference, was carried out
using Image lab software.
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3.3

GST Pulldowns of Transfected HEK 293T Cells Do Not Show an Interaction

between ShcC and GFP-Tagged Src
To determine whether individual ShcC domains could bind directly to Fyn or Src,
mammalian expression vectors containing GST-tagged ShcC domains were cotransfected with either EGFP-tagged Fyn or Src expression vectors into HEK 293T cells
using Lipofectamine 2000. Cells were lysed in Interaction buffer (Appendix I) due to
success in our lab using this buffer for GST pulldowns. Each of the individual CH2, PTB,
CH1, and SH2 domains of ShcC were included (refer to Figure 5), as well as the CH2
domain of ShcA as a positive control. In addition, GST alone was used as a negative
control, while Src was immunoprecipitated using the GFP tag and GFP-Agarose
conjugated antibody (Santa Cruz Biotechnology) as a positive control. Each Western blot
contained 50 µg of each whole cell lysate and a 1 mg representative fraction of GST
pulldown. Western blotting was carried out with mouse-anti Src (1:2000; Calbiochem)
and rabbit anti-GST (1:2000, Santa Cruz Biotechnology), with a positive and negative
control (GFP-IP and GST empty vector, respectively). Results indicate there is no
interaction between Src-GFP and any of the GST fusion proteins, though all are present
in the whole cell lysate and GST pulldown lanes (Figure 10). Substituting Fyn-GFP for
Src-GFP also did not yield any interaction (data not shown). This led me to believe that
there could be technical difficulties preventing any GST pulldowns: 1) The solubility of
GST fusion proteins in lysis buffer could be limiting their availability to bind; 2) The
GFP tag on the C-terminus of Fyn and Src could be affecting the ability of ShcC to bind;
or 3) The domain is not functional outside of the full-length protein . The best way to
investigate these possibilities further was to try different lysis buffers and look for the
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relative abundance of these GST fusion proteins in the supernatant and pellet of HEK 293
cell lysates. In addition, it would be wise to obtain an untagged Src construct and
transfect it similarly alongside these GST fusions.

Figure 10. GST-ShcC subdomain fusions and Src-GFP co-transfection studies in HEK
293T cells. GST pulldowns with GST-ShcC CH2 (29 kDa), ShcC PTB (44 kDa), ShcC
CH1 (47 kDa), ShcC SH2 (37 kDa) and ShcA CH2 (31 kDa) were carried out on cell
lysates and relative fractions representative of 1mg of lysate were loaded in each lane in
the right panel. GST presents as one band of 26kDa.The left panel, alternatively,
contains 50µg of each lysate corresponding to the pulldowns in the right panel. N=3.
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3.4

Lysis Buffer has Little to No Effect on GST Fusion Protein Solubility
I investigated the solubility of each GST fusion protein in HEK 293T cells in

order to determine if lysis buffer could be affecting any subsequent GST pulldowns.
First, I transfected each mammalian expression vectors encoding the GST fusion proteins
into HEK cells The following day, plates were split into three 6 cm dishes, and the day
after, each plate was lysed in either standard NP-40 lysis buffer plus inhibitors as
described above, NP-40 lysis buffer +0.1% SDS, or Interaction Buffer. Lysates were
centrifuged at 20,817xg in the Eppendorf 5417R centrifuge for 15 mins and pellets were
broken down by sonication and re-suspended in 200 µL of the same buffer. Next, 50 µg
of each supernatant and pellet were run on a 10% gel under reducing conditions and
subject to Western blotting with rabbit anti-GST. Results indicate that, despite choice of
lysis buffer, the majority of each GST fusion is found in the supernatant (Figure 11).
There are, however, some notable discrepancies. Though interaction buffer demonstrated
the most protein in the supernatant fraction, the reduction in both NP-40 and NP-40
+0.1% SDS protein levels did not correspond with an increase in the pellet, indicating
that there was some loss during the lysis process as all three samples came from the same
original transfection, and thus had the same efficiency. It is also important to note here
that the ShcC CH2 domain, in all three samples, demonstrated a band large in size (40-45
kDa) in the pellet, not seen in the supernatant, and could potentially be an aggregate of
GST-CH2 that was not broken down by SDS in the sample buffer. This was not
investigated further because there was still a considerable amount of GST-CH2 in the
supernatant available for GST-pulldown experiments. After assessing solubility of these
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GST fusions in each lysis buffer, I concluded that Interaction Buffer was the most
appropriate buffer to perform further experiments.

Figure 11. The effect of lysis buffer on GST fusion protein solubility following overexpression
in HEK 293T cells. The GST-tagged domains of ShcA CH2 (31 kDa), ShcC CH2 (29 kDa), PTB
(44 kDa), CH1 (47 kDa), and SH2 (37 kDa) were present primarily in the supernatant fraction of
HEK 293T cell lysates. A 50µg aliquote of both pellet (left) and supernatant (right) of each GST
fusion protein was loaded. N=1.
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3.5

GST Pulldowns of Transfected HEK 293T Cells Do Not Show an Interaction

between ShcC and Untagged Src
To determine whether the GFP tag of Src-GFP was limiting the interaction
between ShcC and Src in vitro, the GST fusion protein experiment shown in Figure 10
was repeated using instead a Src vector which did not have a tag on the C-terminal end.
Each of the CH2, PTB, CH1, and SH2 domains of ShcC were included, as well as ShcA
CH2 as a positive control and GST alone as a negative control. Results indicate there is
still no interaction between Src and any of the GST subdomain fusion proteins, though all
are present in both the whole cell lysate and GST pulldown lanes (Figure 12). Having
tested both the solubility of GST fusion proteins and the effect of the GST fusion protein
tag, it was determined that neither affected the ability of Src to come down with the GSTShcC subdomain vectors. Therefore, there is no direct interaction between ShcC
subdomains and Src in HEK 293 cells, in contrast to co-IP studies in mouse brain. This
experiment was then attempted in parallel using bacterially-purified GST-ShcC
subdomain constructs (pGEX vector system) and mouse brain lysate as the source of Fyn
and/or Src in section 3.6.
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Figure 12. GST-ShcC subdomain fusions and untagged Src co-transfection studies in
HEK 293T cells. GST pulldowns with GST-ShcC CH2 (29 kDa), ShcC PTB (44 kDa),
ShcC CH1 (47 kDa), ShcC SH2 (37 kDa) and ShcA CH2 (31 kDa) were carried out on
cell lysates and relative fractions representative of 1mg of lysate were loaded in each
lane in the right panel. The left panel, alternatively, contains 50µg of each lysate
corresponding to the pulldowns in the right panel. An immunoprecipitation for Src was
included as a positive control, in substitute of an IP to GFP. Western Blotting was
carried out with 1:2000 mouse-anti V-Src and 1:2000 rabbit-anti GST. N=3.
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3.6

ShcC Binds Endogenous Fyn Through its CH2 and SH2 Domains
As an alternate approach to examine ShcC interactions with Fyn or Src, each

domain of ShcC was cloned into pGEX for expression of a GST-fusion protein with an
IPTG-inducible promoter (GST-PTB and GST-SH2 were previously cloned by Ian
Grant). GST fusion proteins were quantified and assessed for purity and used for GST
pulldowns with 2 µg of bacterially purified GST fusion proteins (pGEX-, ShcA CH2,
ShcC CH2, PTB, CH1, and SH2) and 2-4 mg of fresh CD-1 mouse brain lysate prepared
in NP-40 as described above. The resultant pulldowns were electrophoresed on 10%
polyacrylamide gels and blotted first for mouse anti-Fyn (Abcam), or rabbit anti-Src, and
second for rabbit anti-GST (Santa Cruz Biotechnology). Results indicate an interaction
between the CH2 and SH2 domains of ShcC with Fyn in lysates prepared from both P8
and P21 brains (Figure 13A and B). As there is some background at both P8 and P21, the
relative band intensities were compared to the GST negative control, and both ShcC CH2
and ShcC SH2 signal intensities were above background at P7 and P21 (Figure 13C).
There were some technical difficulties with this experiment, mainly GST fusion protein
degradation resulting in unequal protein loading. After several attempts, and adaptations
(i.e., quantifying GST fusion proteins the day of the pulldown), I was not able to obtain a
replicate where GST fusion protein levels were relatively equal in each lane. Though the
results might not be 100% convincing, they do indicate that ShcC is capable of binding to
Fyn through its CH2 and SH2 domains, further supporting my hypothesis. This also
demonstrates that, though not observed in mouse co-IPS (Figures 8 and 9), p69 ShcC
should be able to bind to Fyn and/or Src.
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Figure 13. GST pulldown studies using bacterially-purified GST fusion ShcC subdomains
with Fyn at P8 (A) and P21 (B). GST pulldowns from (26kDa) and GST-ShcC CH2 (29
kDa), ShcC PTB (44 kDa), ShcC CH1 (47 kDa), ShcC SH2 (37 kDa) and ShcA CH2 (31
kDa) were carried out on whole brain lysates and relative fractions representative of 1mg
of lysate were loaded in each lane, with 50µg of the same mouse brain lysate as a positive
control. N=1 for each (A) and (B). Successful GST pulldowns are denoted by an asterisk
(*) to the left of the indicated band. C) Quantification of relative band intensity of Fyn,
using GST as a reference, was carried out using Image lab software.
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3.7

Tyrosine Phosphorylation of GST ShcC CH1SH2 when Co-Purified with V-Src
To determine the importance of tyrosine phosphorylation in SH2 domain binding

properties I took a two-fold approach: I generated a phosphomimetic form of ShcC
(pGEX ShcC CH1SH2 Y221, 222, and 304E; 3YE) that does not contain the PTB
domain, as well as co-expressing the native form of this vector (pGEX ShcC CH1SH2)
with bacterially-expressed viral Src (pET28a) to allow for tyrosine phosphorylation.
These tyrosine residues were chosen as phosphorylation at these three sites were shown
to be essential for SH2 domain activity in ShcA (George et al., 2008). This protein has an
empirically-determined size of approximately 62 kDa (Figure 14). Following GST fusion
protein purification, 0.5-1µg of each GST fusion protein was run beside Daoy-TrkA
(NGF-responsive medulloblastoma cell line) cell lysate with 10 minutes of NGF
stimulation, provided by a former lab member, Chunhui Li, and Western Blotting was
carried out with 1:2000 Mouse anti-Phosphotyrosine (Cell Signaling). Preliminary results
indicate some tyrosine phosphorylation in GST-CH1SH2 when expressed with V-Src
(Figure 15). However, this strain of E. coli (XL10-gold) does not possess the necessary
RNA polymerase (T7) to properly express from the pET28a (T7) promoter, and vectors
were then re-transformed into a BL21-DE3+ strain. Tyrosine phosphorylation may still
be witnessed because there was a low level of expression of pET28a V-Src, enough to
phosphorylate some protein. I then transferred the pGEX (empty vector ShcC CH1,
CH1SH2, and 3YE) vectors alongside pET28a (empty vector or V-Src) vectors into
BL21-DE3+ strain of E. coli, and tyrosine phosphorylation is much more discernible
(Figure 16). Both pGEX ShcC CH1SH2 and 3YE, when co-purified with V-Src, are
tyrosine phosphorylated (Figure 16). This result indicated that ShcC can be tyrosine
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phosphorylated at other sites than 221, 222, and 223, as the phosphomimetic (3YE) ShcC
did not contain them, yet tyrosine phosphorylation was still visible. However, ShcC CH1
alone was not tyrosine phosphorylated by V-Src, indicating that V-Src showed specificity
to ShcC CH1SH2 over ShcC CH1. In addition, though no tyrosine phosphorylation was
observed in the GST (empty vector) lane, upon re-probe for GST no band of the correct
size was present, indicating the the protein was not there and likely ran off the gel due to
its small size (26 kDa) in this case.

Figure 14. Quantification of GST-ShcC CH1SH2 and CH1SH2 3YE (62 kDa) with
respect to BSA standards (Bio-Rad; 66 kDa). Shown here is an example gel; samples
were quantified by utilization of the ImageLab software and amounts of protein are
shown below the appropriate gel bands.
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Figure 15. GST-ShcC CH1SH2 (65kDa) in the presence of V-Src in the cloning strain
of E. coli, XL10-Gold. GST-ShcC CH1 (47 kDa) was also included, in addition to
GST-ShcC CH1SH2 3YE, which does not contain the three tyrosines in the CH1
domain. As a positive control, 50µg of NGF-treated Daoy-TrkA cell lysate was used.
Note: potential bands of the appropriate size of 47 kDa (ShcC CH1) or ~62 kDa (ShcC
CH1SH2) are denoted by an asterisk (*). N=1.

Figure 16. Tyrosine phosphorylation assessment of GST-ShcC CH1SH2 (65kDa) in the
presence of pET28a empty vector (-) or pET28a V-Src (+) in the expression strain of E.
coli, BL21-DE3. Western Blotting was first carried out with 1:2000 mouse-anti
Phosphotyrosine, and then for rabbit-anti GST. As a positive control, 50µg of NGFtreated Daoy-TrkA cell lysate was used. For phosphotyrosine assessment, only the area
of the blot with detected bands was shown. Note: Bands of appropriate size for GST
fusion proteins of 47 kDa (ShcC CH1) or ~62 kDa (ShcC CH1SH2) are denoted below
the band by an asterisk (*). N=1.
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3.8

Tyrosine Phosphorylation is Important for SH2 Domain Binding
The phosphomimetic mutant of ShcC (3YE) described above, along with ShcC

CH1SH2, were co-purified in the presence and absence of V-Src, and 2 µg of these
fusion proteins were incubated with 2-4 mg CD-1 mouse brain as described above to pull
down any potential SH2 binding partners. As a negative control, the CH1 domain of
ShcC was also co-purified with V-Src. Results indicated an interaction between tyrosine
phosphorylated ShcC with Fyn or Src at P8 (Figure 17A and B). As there is some
background in Figure 17B, the relative band intensities were compared to GST. GST
ShcC CH1SH2 + V-Src signal intensities were above background when probing for Fyn
or Src (Figure 17C). An interaction between ShcC CH1SH2 3YE and Fyn was seen only
once (data not shown), suggesting that using glutamic acid substitution did not correctly
mimic tyrosine phosphorylated ShcC. Upon transformation of the aforementioned vectors
into BL21-DE3+ E. coli, this experiment was repeated to assess whether or not results
would change. However, to date this has only been attempted once and, with the change
in strain, the optimization process needs to be repeated to eliminate the background now
seen when blotting for Src (Figure 18). As with the GST-subdomain pulldown
experiment (Figure 13), there were some technical difficulties. Apart from being unable
to see tyrosine phosphorylation prior to transforming the vectors into BL21-DE3+ E. coli,
there were also problems with GST fusion protein degradation, resulting in unequal
amounts of GST fusion protein. In addition, once in BL21, there was signal background
in the GST pulldowns when blotting for Fyn, such that signal was virtually
indistinguishable from background. The inferences we can make from Figure 17,
however, are that tyrosine phosphorylation is important for ShcC binding to Src or Fyn.
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Figure 17. GST pulldown studies
using bacterially-purified GST
fusion ShcC in the absence of the
PTB domain. A) and B) GST
pulldowns were implemented
with ShcC CH1SH2 in the
presence or absence of V-Src, and
phosphomimetic ShcC CH1SH2
3YE (all ~62 kDa). Successful
GST Pulldowns are indicated by
an asterisk (*). GST ShcC CH1
was co-purified in the presence of
V-Src as a negative control in
(B). Note: an asterisk (*) below a
band in the lower panel of (B)
denotes band of the correct size
for GST-ShcC CH1. N=3. C)
Quantification of relative band
intensity of Fyn in (A), Src in (B),
using GST as a reference, was
carried out using Image lab
software.
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Figure 18. GST pulldown studies using bacterially-purified GST fusion ShcC CH1,
CH1SH2, and CH1SH2 3YE in BL21-DE3+ cells. GST pulldowns were implemented
in the presence or absence of V-Src. Western Blotting was carried out, as previously
described, with 1:2000 rabbit-anti Src and 1:2000 rabbit-anti GST. The GST reprobe
was separated here due to the presence of the Src band in the middle. N=1.
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Chapter 4. Discussion
There is considerable evidence to support the working model that ShcC is
involved in NMDA receptor activity during LTP. As ShcC is generally activated by TrkB
(Rozakis-Adcock et al., 1992), this provides a potential mode for receptor cross-talk
between TrkB and NMDA receptors. First and foremost, ShcC knockout mice
demonstrate enhance hippocampal LTP and an increase in tyrosine phosphorylation of
the NMDA receptor subunits NR2A and NR2B, but there were no differences in Src
family kinase phosphorylation at the active site (Miyamoto et al., 2005). The authors also
performed an in vitro Src kinase assay and demonstrated that there was no difference in
Src family kinase activity (Miyamoto et al., 2005). However, there is new evidence to
support that Shc(A) can regulate the activity of Src family kinases differentially through
its two isoforms, p52 Shc and p66 Shc (Xi et al., 2010a), and therefore the association of
ShcC with Src family kinases in the brain warrants further investigation.
There is also evidence to support the association of Shc family members with the
Src family kinases. Both p52 and p66 ShcA were shown to bind to Src, whereas ShcC
was shown to bind to one of the Src family kinases, but the specific kinase was not
determined (Miyamoto et al., 2005; Xi et al., 2010a). I investigated the binding properties
of ShcC with respect to Fyn and Src, and observed a co-immunoprecipitation between
p55 ShcC and both Fyn and Src, and between p69 ShcC and Src (Figures 8 and 9). In
addition, after many attempts I was unable to observe an interaction between either ShcC
isoform and STEP (Figure 9b). The interaction between ShcC and Fyn or Src was albeit
weak, and required more than 2mg of protein during the IP. If the IP was attempted with
2 mg or less, even though only a 1 mg representative fraction was loaded on each
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Western Blot, a co-IP was not seen (data not shown). A weak co-IP could be an indicator
of an activity-dependent or transient interaction. This interaction is likely activitydependent, however, as Shc binding to Src in smooth muscle cells is dependent on IGF-1
stimulation, it is likely interaction is activity-dependent (Xi et al., 2010a).
The interaction of ShcC and Src family kinases is thus likely mediated by TrkB
activation in this case. Knowing that Fyn kinase is the key player in NMDA receptor
tyrosine phosphorylation (Grant et al., 1992), these results, taken together, lead me to
believe the cross-talk between TrkB and NMDA is mediated by ShcC interaction with
Fyn kinase, though it may also signal through Src kinase. There is also an explanation of
why I did not observe an interaction between p69 ShcC and Fyn: at the overall level, p55
ShcC is much more abundant (Figure 6) and, since I only studied co-IPs in whole brain,
not stimulated cells, it is likely the small amount of p69 ShcC was not visible. To test this
idea, it would be beneficial to co-express either p55 or p69 ShcC with Fyn in PC12 cells,
and stimulate with NGF. Alternatively, our lab has a mutagenized form of PC12 cells
lacking TrkA and stably-expressing TrkB, termed TrkB-B5, which would respond to
BDNF. I predict that, when cells are stimulated with either NGF of BDNF, I would see
an increase in the interaction between p69 ShcC and Fyn.
Despite the lack of change in Src family kinase activity in ShcC knockout mice,
the association of ShcC and Src family kinases is still worth investigating as there is
promising evidence to support a role for Shc family members in regulating Src family
kinase activity. It was demonstrated that p66 Shc presence, or over-expression of p66
Shc, interrupted p52 Shc activation by IGF-1 stimulation and prevented Grb2 association,
resulting in impaired MAP kinase or PI3-kinase activation (Xi et al., 2008; Xi et al.,
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2010a; Xi et al., 2010b). In fact, p66 Shc inhibited the activation of p52 Shc via tyrosine
phosphorylation by Src, indicating that the presence or over-expression of p66 Shc might
also be binding to Src (Xi et al., 2008; Xi et al., 2010a). Following logically, association
of p66 Shc and Src was investigated. It was then demonstrated that p66 Shc bound
directly to Src through its CH2 (polyproline) and SH2 domains, to the SH3 and catalytic
(SH1) domains of Src, respectively, and that binding of p66 Shc inhibited IGF-1dependent Src kinase activation (Xi et al., 2010a). Src family kinases are folded in their
inactive form and upon tyrosine phosphorylation in the kinase domain (416 on Src, 420
on Fyn) there is a conformational change resulting in activation (Superti-Furga et al.,
1993; Sun et al., 1998; Nguyen et al., 2002). Expression of the CH2 domain alone could
also attenuate Src kinase activity, but not to the extent of full-length p66 Shc (Xi et al.,
2010a). Alternatively, p66Shc-SH2 deletion mutant expression did not affect Src family
kinase activity, implicating the CH2-SH3 interaction as the inhibitor of Src kinase
activation (Xi et al., 2010a). This led researchers to believe that p66 Shc binding to Src
resulted in an either a prevention of Src unfolding, or an allosteric change, preventing its
activation (Xi et al., 2010a). In support of this notion, using an inhibitory peptide to block
the polyproline-SH3 interaction rescued Src kinase activation (Xi et al., 2010a).
In my research, I observed an interaction of both the CH2 and SH2 domains of
ShcC with Fyn utilizing bacterially-purified GST fusion proteins to each (Figure 13),
consistent with literature on ShcA and Src (Xi et al., 2010a). To further this notion, it
would be interesting to break Fyn down into its subdomains (namely SH3, SH2, and
SH1) to ascertain which could bind to full-length ShcC, or to individual ShcC domains.
By convention, a different tag would be used (i.e. Myc) so both vector sets could be used
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simultaneously. These experiments may also indicate the potential for p69 ShcC to bind
to Fyn or Src, which was not witnessed in co-IP studies from mouse whole brain (Figures
8 and 9). To further investigate the potential for p69 ShcC to bind to Fyn and Src, it
would be advantageous to co-express p55 or p69 ShcC with Fyn or Src in PC12 cells as
described above. To ascertain whether or not p69 ShcC could inhibit Src family kinase
activation, an in vitro kinase assay could be implemented as previously used on both
ShcA and ShcC (Miyamoto et al., 2005; Xi et al., 2010a). I would co-express either p55
or p69 ShcC with Fyn in PC12 or TrkB-B5 cells and stimulate with NGF or BDNF,
respectively, to measure kinase activity. As neurotrophin-mediated enhancement of
NMDA receptor activity is often shown to be BDNF-specific, it would be beneficial to
use both PC12 and TrkB-B5 cells, to evaluate whether interaction between ShcC
isoforms and Fyn is also specific to TrkB-activation of ShcC upon BDNF administration
(Suen et al., 1997; Levine et al., 1998; Lin et al., 1998; Crozier et al., 1999; Nakazawa et
al., 2001).
I was unable to support the data suggesting both CH2 and SH2 domains of ShcC
bind to Fyn by co-expressing GST-tagged ShcC domains with Src in HEK 293T cells
(Figures 10 and 12). Through troubleshooting, I have shown that protein solubility in
lysis buffer is not likely the cause (Figure 11), nor is the GFP tag on the N-terminus of
Src (Figure 12) as using an untagged form did not influence the lack or Src interaction.
This does not however take into account any potential confounding variables of using an
artificial system to investigate binding capabilities. For example, it is possible that ShcC
and Fyn/Src, though present as the part of the same complex in the mouse brain, do not
actually bind to each other directly and require a third protein to mediate the interaction,
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in contrast to the direct binding of ShcA and Src (Xi et al., 2010a). Absence of that third
protein in this artificial system could result in a false negative result. Secondly, if the
proteins are not properly solubilized when overexpressed in HEK 293T cells, or if
aggregation occurs, constituents may not be available to bind to each other and therefore
can also lead to a false negative. This insolubility is in fact seen with the ShcC CH2
domain, where I witnessed a band in the pellet fraction that was much too large (Figure
11). This must not be confused with protein insolubility in lysis buffers, as the use of
several tested lysis buffers did not change these results (Figure 11). Third, it is also
possible that subcellular localization plays a role in the inability of ShcC to bind to
Fyn/Src. In the brain, ShcC and Fyn/Src are localized to the post-synaptic density, which
is held together by a scaffolding protein, PSD-95. Without this regulation and colocalization binding may not occur.

Fourth, using a subdomain approach to study

binding has its disadvantages, in particular to those with multi-domain binding. If there is
mutual attraction of both ShcC and Fyn during binding, this scenario may eliminate
necessary elements for one protein to recognize and/or recruit the other. This could be
addressed by running a similar experiment with full length ShcC as described above. In
addition, using a subdomain approach may not allow for proper domain folding improper
structure would influence results of the study. Lastly, it is also possible that if co-IPs
from mouse brain are not reproducible by another means, there is no direct interaction.
However, this is an unlikely scenario: although co-expressing GST subdomain vectors of
ShcC with Src in HEK 293 cells did not indicate an interaction (Figures 10 and 12), this
was successful using bacterially-purified GST fusions incubated with mouse brain
(Figure 13).
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There exists additional evidence to support the importance of tyrosine
phosphorylation in the CH1 domain of ShcC at Y221, 222, and 304 in SH2 domain
activity. George et al (2008) demonstrated that, when three critical tyrosines in the CH1
domain of ShcA were mutated to phenylalanine (3F), the SH2 domain was unable to bind
its targets. In fact, SH2 domain binding was only witnessed when these three tyrosines
were phosphorylated (George et al., 2008). A phosphomimetic, where these tyrosines
were mutated to aspartic acids, did also not result in any SH2 domain binding. In turn, I
generated a GST fusion ShcC construct lacking the PTB domain (pGEX CH1SH2) with
glutamic acid substitutions at the three critical tyrosines (3YE) in an attempt to study SH2
domain binding partners. In parallel, I co-expressed the native form of ShcC CH1SH2
with V-Src (in pET28a). I used ShcC CH1 as a negative control to be more confident that
any identified binding partners were interacting through the SH2 domain. I have
demonstrated that a tyrosine-phosphorylated ShcC construct (pGEX ShcC CH1SH2) was
capable of pulling down Fyn or Src whereas the non-tyrosine phosphorylated form was
unable to bind (Figure 17). However, I did not consistently witness an interaction with
the phosphomimetic form. It is also noteable that GST-ShcC SH2 is capable of pulling
down Fyn (Figure 13) whereas GST-ShcC CH1SH2 is not able to unless it is tyrosine
phosphorylated (Figure 17), indicating a potential functional role of tyrosine
phosphorylation when the CH1 and SH2 domains are together as they are in the
endogenous protein. However, after re-transforming the vectors into the DE3+ BL21
strain of E. coli, I was able to observe tyrosine phosphorylation of both CH1SH2 and
CH1SH2 3YE when co-purified with V-Src (Figures 15 and 16). This indicates that VSrc also phosphorylated tyrosine residues other than 221, 222, and 304 (not present in the
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3YE mutant). Alternatively, ShcC CH1 alone did not show any tyrosine phosphorylation
(Figure 16) indicating that V-Src did have some specificity for CH1SH2 over CH1 alone.
However, repeating GST pulldowns with proteins expressed and purified from the BL21DE3+ strain did not yield the same result (Figure 18) and this experiment requires further
optimization. It is important to note that ShcC CH1SH2, when co-purified with V-Src in
a cloning strain of E. coli, resulted in an interaction between ShcC CH1SH2 and Fyn or
Src (Figure 17A and B, respectively), indicating that though V-Src expression was not
constitutive when proteins were expressed and purified in XL10-gold cells, due to the
lack of a T7 RNA polymerase to express from the pET28a T7 promoter, there was some
baseline expression that was sufficient to phosphorylate some of the ShcC CH1SH2
protein (Figure 15). This experiment needs to be optimized in the BL21 strain though,
however, to be more confident in the results.
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In conclusion, I determined that ShcC binds to Fyn through its CH2 and SH2
domains. If this is truly the case, this could explain why ShcC knockout mice have
increased NR2B tyrosine phosphorylation (Miyamoto et al., 2005). However, based on
the literature, it is only p69 ShcC that has the potential to inhibit Src kinase activation (Xi
et al., 2010a). Perhaps it is the ratio of p55 to p69 ShcC that governs the regulation of Src
and Fyn kinases. Perhaps there are still other players that need to be identified.
Nonetheless, ShcC or Fyn represent potential drug targets to treat learning disorders: By
blocking the cross-talk between p69 ShcC and Fyn, but not p55 ShcC and Fyn, we could
up-regulate NR2B tyrosine phosphorylation and resultant learning and memory. This
could be studied by knocking-in p55 ShcC in a ShcC knockout mouse, or by knocking-in
a non-splicable form of p69 ShcC, and studying their learning capabilities compared to
both wild-type and total ShcC knockout mice. ShcC binding partners in the hippocampus
have the potential to be the targets of treatment for learning disorders.
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Appendix 1. Supplementary Materials and Methods
Table I. List of all Vectors used, origin, expression type, and both predicted and
empirical size.
Vector Name

Size (kDa)

pEBG

Source
P. Angborg

Expression
Mammalian

pEBG ShcA CH2

Kayla Driver

Mammalian

31

pEBG ShcC CH2

Kayla Driver

Mammalian

29

pEBG ShcC PTB

Ian Grant

Mammalian

44

pEBG ShcC CH1

Kayla Driver

Mammalian

47

pEBG ShcC SH2

Ian Grant

Mammalian

37

pET28a

Novagen

Bacterial

N/A

pET28a V-Src

Kayla Driver

Bacterial

60

pGEX 4T-2

Pharmacia

Bacterial

26

pGEX ShcA CH2

Kayla Driver

Bacterial

31

pGEX ShcC CH2

Kayla Driver

Bacterial

29

pGEX ShcC PTB

Hui-Yu Liu

Bacterial

44

pGEX ShcC CH1

Kayla Driver

Bacterial

47

pGEX ShcC SH2

Ian Grant

Bacterial

37

pGEX ShcC CH1SH2

Kayla Driver

Bacterial

57/62

pGEX ShcC CH1SH2 3YE

Kayla Driver

Bacterial

57/62

pcDNA 4/T.O. Src(1-532)-GFP

26

Mammalian

87

pcDNA 4/T.O. Fyn(1-536)-GFP

Naoto Yamaguchi
(Kasahara et al. 2007)

Mammalian

86

pCMV5 C-Src

Joan Brugge (Addgene) Mammalian

60

pEGFP-C1

Clontech

27

Mammalian

Note: Protein sizes indicated with two numbers (i.e. 57/62) indicate first predicted, then
empirically determined protein sizes.
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Table II. List of all Antibodies used for immunoprecipitation and/or Western Blotting,
company purchased from, and all applicable dilutions.
Antigen

Species

Company

Immunoprecipitation Western Blot

β-Actin

Mouse

Sigma-Aldrich

N/A

1:10,000

Fyn

Mouse

Abcam

1µg

1:2000-5000

GFP-AC

Rabbit

Santa Cruz

5-10µg

GFP-FL

Rabbit

Santa Cruz

N/A

1:2000

GST-Z5

Rabbit

Santa Cruz

N/A

1:2000

Phosohotyrosine

Mouse

Cell Signaling

N/A

1:2000

ShcC

Mouse

BD Biosciences

1µg

1:2000-5000

ShcC

Rabbit

Santa Cruz

2µg

1:1000-2000

Src

Rabbit

Cell Signaling

5µL

1:2000

V-Src

Mouse

Calbiochem

N/A

1:2000

STEP

Mouse

Santa Cruz

2µg

1:1000-2000

STEP

Rabbit

Cell Signaling

5µL

1:2000

N/A

Note: Immunoprecipitation amounts are listed as either volume (in µL) or quantity (in
µg) added to 1mL final volume of the IP; Western blot concentrations are listed as a
ratio to 10mL final volume blocking buffer (i.e. 1:2000 represents 5µL in 10mL final
volume).
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List of Buffers, Reagents, and Their Constituents, in Order of Appearance
TFBI
100mM
Rubidium chloride
50mM
Manganese chloride
30mM
Potassium acetate
10mM
Calcium chloride
15%
Glycerol
Adjusted to pH 5.8 with 1M Acetic Acid
TFBII
10mM
10mM
75mM
15%

MOPS
Rubidium chloride
Calcium chloride
Glycerol
Adjusted to pH 6.5 with KOH.

LB Media and Plates
Note: LB was autoclaved in bottles or flasks, LB Agar plates were autoclaved and then
poured into petri dishes and stored at 4ºC. Per 500mL:
5g
Bio-Tryptone (Bioshop)
2.5g
Yeast Extract (Bioshop)
5g
NaCl
7.5g
Agar (for plates only)
Solution I
2.5mM
10mM
50mM

Solution II
1%
200mM
Solution III
3M
1.18M

TE
1M
500mM

Tris-Cl (pH 8.0)
EDTA
Glucose
pH to 8.0, store at 4ºC.
SDS
NaOH
Potassium Acetate
Acetic Acid
pH to 5.5, store at 4ºC.
Tris pH 8
EDTA
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HEK 293T Media
450 mL
50 mL 10%
500µL 50µg/mL

Dulbecco’s modified Eagle's medium (Wisent)
Fetal Bovine Serum (Wisent)
Gentimycin Sulfate ( Company)

2.5M CaCl2 for Calcium Phosphate Transfection
183.7g
CaCl2·2H2O
H2O to 500mL. Filter sterilize through 0.45µM mesh, store 10mL
aliquots at -20ºC.
2X HBSS (HEPES-Buffered Saline Solution)
0.28M
NaCl
0.05M
HEPES
1.5MM
Na2HPO4
Add 4/5 volume H2O, triturate to pH 7.5 with 5M NaOH, top to
final volume.
PBS (10X)
Note: To make 1X, 100mL was diluted in 900mL dH2O.
40g
NaCl
1g
KCl
7.2g
Na2HPO4
1.2g
KH2PO4
H2O to 500mL. Adjust pH to 7.4 with NaOH.
NP-40 Lysis Buffer
50mM
137mM
1mM
1%
10%

Tris (pH 8.0)
NaCl
EDTA
NP-40
Glycerol

Interaction Buffer
20mM
150mM
0.1%
10%

HEPES (pH 7.5)
NaCl (5M)
NP-40
Glycerol

PBS Lysis I
2mM
1mM
10µg/mL

PBS (1X)
EDTA
Sodium Vanadate, PMSF
Aprotinin, Leupeptin
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PBS Lysis II
Note: PBS Lysis II was prepared using PBS (10X) and made up with dH2O.
1%
Triton X-100 (20%)
2mM
EDTA (0.5M)
1mM
Sodium Vanadate, PMSF
10µg/mL
Aprotinin, Leupeptin
SDS-PAGE Sample Buffer (5X)
1mL
20% SDS
0.6mL
1M Tris-Cl (pH 6.8)
2.4mL
Glycerol
1mL
10% Bromophenol Blue
H2O to 10mL, aliquot 1mL each and store at -20ºC. Prior to use, at
15.1mg DTT (Bioshop).
Lower Tris
36.34g
8mL
Upper Tris
12.12g
8mL

Tris
10% SDS
H2O to 200mL, adjust pH to 8.8, filter sterilize, then add SDS.
Tris
10% SDS
H2O to 200mL, adjust pH to 6.8, filter sterilize, then add SDS.

30% Acrylamide/Bis-Acrylamide
150g
Acrylamide
4g
Bisacrylamide
H2O to 500mL, filter sterilize.
SDS-PAGE Buffer (10X)
121.6g
Tris
577.6g
Glycine
40g
SDS
H2O to 4L.
Transfer Buffer (10X)
Note: To make 1X, 100mL was diluted in 200mL methanol and 700mL dH2O.
29g
Tris
144g
Glycine
H2O to 1L.
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TBS (10X)
24.2g
80g

TBS-Tween (1X)
100mL
900mL
1mL

Tris
NaCl
H2O to 1L. Adjust pH to 7.6 with HCl.
10X TBS
dH2O
Tween-20

BSA Blocking Buffer (10X)
20g
BSA
200mM
Tris (pH 7.2)
2M
NaCl
0.1%
Tween-20
H2O to 100mL. Filter sterilize.
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